

CARINI APARECIDA LELIS

**INTERAÇÕES INTERMOLECULARES ENTRE PROTEÍNAS DO SORO DO LEITE E
MOLÉCULAS DE INTERESSE NA ÁREA DE ALIMENTOS**

Tese apresentada à Universidade Federal de Viçosa,
como parte das exigências do Programa de Pós-
Graduação em Ciência e Tecnologia de Alimentos,
para obtenção do título de *Doctor Scientiae*.

VIÇOSA
MINAS GERAIS - BRASIL
2019

**Ficha catalográfica preparada pela Biblioteca Central da Universidade
Federal de Viçosa - Câmpus Viçosa**

T
L541i
2019
Lelis, Carini Aparecida, 1989-
Interações intermoleculares entre proteínas do soro do leite
e moléculas de interesse na área de alimentos / Carini Aparecida
Lelis. – Viçosa, MG, 2019.
xii, 51 f. : il. (algumas color.) ; 29 cm.

Orientador: Ana Clarissa dos Santos Pires.
Tese (doutorado) - Universidade Federal de Viçosa.
Inclui bibliografia.

1. Curcumina. 2. Enrofloxacina. 3. Soro do leite - Proteínas.
4. Forças intermoleculares. I. Universidade Federal de Viçosa.
Departamento de Tecnologia de Alimentos. Programa de
Pós-Graduação em Ciência e Tecnologia de Alimentos.
II. Título.

CDD 22. ed. 667.26

CARINI APARECIDA LELIS

**INTERAÇÕES INTERMOLECULARES ENTRE PROTEÍNAS DO SORO DO
LEITE E MOLÉCULAS DE INTERESSE NA ÁREA DE ALIMENTOS**

Tese apresentada à Universidade Federal de Viçosa, como parte das exigências do Programa de Pós-Graduação em Ciência e Tecnologia de Alimentos, para obtenção do título de *Doctor Scientiae*.

APROVADA: 28 de fevereiro de 2019.



Manoela Maciel dos Santos Dias



Tiago Antônio de Oliveira Mendes



Marcia Cristina Teixeira Ribeiro Vidigal



Luis Henrique Mendes da Silva
(Coorientador)



Ana Clarissa dos Santos Pires
(Orientadora)

AGRADECIMENTOS

A Deus, pela oportunidade oferecida, pelo conforto nos momentos de angústia e por me iluminar nos momentos de escuridão.

Aos meus pais, José e Lúcia, aos meus irmãos Camila e Mateus por todo apoio, paciência, amizade, amor e incentivo em mais essa etapa.

À Universidade Federal de Viçosa e ao Departamento de Tecnologia de Alimentos, pela oportunidade de realização do curso.

A Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, pela concessão da bolsa de estudo. A CNPq, FAPEMIG e Vale S. A. pelo financiamento do projeto.

A minha orientadora, professora Ana Clarissa dos Santos Pires, pela orientação, ensinamentos, apoio, diálogo, incentivo e confiança proporcionados.

Ao meu co-orientador, professor Luís Henrique Mendes da Silva, pelos ensinamentos, colaboração e assistência na realização desse trabalho. Pela disponibilização do uso de equipamentos do seu laboratório sempre que necessário.

Ao meu co-orientador, professor Nélio José de Andrade pelos ensinamentos, confiança e parceria.

Aos professores Márcia Cristina Teixeira Ribeiro Vidigal, Manoela Maciel dos Santos Dias e Tiago Antônio de Oliveira Mendes pela participação na banca de defesa.

Aos amigos do THERMA, pela amizade, pelo auxílio no desenvolvimento do trabalho e por me engrandecer como pessoa e profissional.

A todos do QUIVECOM pela ajuda na realização de análises do experimento.

A todos os colegas da Pós-Graduação pela agradável convivência e incentivos.

A todos, que de alguma forma, foram importantes para a realização deste trabalho.

BIOGRAFIA

Carini Aparecida Lelis, filha de José Francisco de Oliveira Lelis e Lúcia Eunice do Carmo Lelis, nasceu em Viçosa, Minas Gerais, em 03 de abril de 1989.

Em março de 2008, ingressou no curso de Ciência e Tecnologia de Laticínios na Universidade Federal de Viçosa (UFV), graduando-se em novembro de 2012.

Em abril de 2013 iniciou o mestrado no Programa de Pós-Graduação em Ciência e Tecnologia de Alimentos, na Universidade Federal de Viçosa, obtendo seu título em fevereiro de 2015.

Em março de 2015 iniciou o doutorado no Programa de Pós-Graduação em Ciência e Tecnologia de Alimentos, na Universidade Federal de Viçosa, submetendo-se à defesa de tese em fevereiro de 2019.

SUMÁRIO

LISTA DE FIGURAS	vi
LISTA DE TABELAS	viii
RESUMO	ix
ABSTRACT	xi
INTRODUÇÃO GERAL	1
Capítulo 1: Lactoferrin-curcumin binding: a thermodynamic, and kinetic study of an important biofunctional complex.....	3
Abstract	3
Keywords	3
1. Introduction.....	4
2. Material and Methods	6
2.1. Materials.....	6
2.2. Fluorescence Experiments.....	6
2.3. SPR experiments.....	6
3. Results and Discussion	7
3.1. Fluorescence Measurements	7
3.2. SPR Measurements	12
3.2.1. Energetic parameters of formation of bLF-CUR activated complex.....	18
4. Conclusions	23
Acknowledgments	23
5. References	23
Capítulo 2: Interactions of enrofloxacin with bovine serum albumin: A detailed thermodynamic study by fluorescence spectroscopy	31
Abstract	31
Keywords	31
1. Introduction.....	31
2. Material and Methods	33
2.1. Material.....	33
2.2. Fluorescence experiments.....	33
2.2.1. BSA-ENRO binding.....	33
2.2.2. Competitive binding studies	34
3. Results and Discussion	34

3.1. Binding of ENRO on BSA studied by fluorescence spectroscopy	34
3.2. Thermodynamic parameters for ENRO–BSA binding	37
4. Conclusions	43
Acknowledgments	43
5. References	43
CONCLUSÕES GERAIS.....	51

LISTA DE FIGURAS

Capítulo 1

Figura 1. Fluorescence emission spectra of 3.0 μM bLF in the presence of 0, 2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 17.5, 20.0, 22.5, 25.0 μM CURC at pH 7.4.....	8
Figura 2. The plot of $\log[(F_0-F)/F]$ as a function of $\log [Q]$, being binding constant (Kb) the intercept and stoichiometry (n) the slope at pH 7.4.....	9
Figura 3. Sensograms (RU vs. time) for bovine lactoferrin -curcumin binding at 298 K and pH 7.4. The arrows indicates increasing CUR concentration (30-100 μM).....	12
Figura S1. Plots of k_a (■) and k_d (○) versus T for bLF-CUR interaction at pH 7.4. Polynomial equation for association process: $k_a = 0.003 (T)^2 - 1.89 (T) + 274.40$; $R^2 = 0.96$ and for dissociation process: $k_d = 0.001 (T)^2 - 0.98 (T) + 143.72$; $R^2 = 0.86$	14
Figura 4. Enthalpy–entropy compensation plot of bLF-CUR binding.	17
Figura 5. Plot of variation of the standard molar enthalpy change (ΔH°) versus temperature for the bLF-CUR binding.....	18
Figura S2. $\ln k_a$ (■) and $\ln k_d$ (○) versus the inverse of temperatures associated with the interaction between bovine lactoferrin and curcumin at a pH of 7.4. Polynomial equation for association process: $\ln k_a = 1.62 \times 10^7 (1/T)^2 - 1.12 \times 10^6 (1/T) + 201.58$; $R^2 = 0.97$, and for dissociation process: $\ln k_d = 4.06 \times 10^7 (1/T)^2 - 2.78 \times 10^6 (1/T) + 437.17$; $R^2 = 0.89$	20
Figura 6. Plot of kinetic activation energetic parameters versus temperature: (Δ) E_{act} , (○) ΔG^\ddagger , (■) ΔH^\ddagger , and (▲) $T\Delta S^\ddagger$ for (a) association and (b) dissociation phases.....	21
Figura 7. The formation of bLF-CUR activated complex dependent on the temperature.....	21

Figure 8. $T\Delta S^\ddagger$ vs. ΔH^\ddagger plot for formation of bLF-CUR activated complex from: (■) association of free bLF and CUR, and (○) dissociation of thermodynamically stable bLF-CUR complex.....23

Capítulo 2

Figure 1. Fluorescence spectra of increasing ENRO concentration at 308.15 K and pH 7.4 (λ_{ex} = 315 nm and λ_{em} = 415 nm) in the presence of BSA (3.0×10^{-7} mol.L⁻¹). Arrow indicates an increase in the ENRO concentration (from 0 to 3.0×10^{-6} mol.L⁻¹). (B) - The double reciprocal plot was obtained on the basis of (1), allowing calculation of the inclusion constant value of the complexes of ENRO and the studied BSA.....34

Figure 2. Non-linear van't Hoff plot for binding of BSA (3.00×10^{-7} mol.L⁻¹) and ENRO at different temperatures (pH = 7.4).....38

Figure 3. Enthalpy–entropy compensation plot of binding BSA-ENRO.....40

Figure 4. Plot of variation of the standard molar enthalpy change (ΔH°) versus temperature for the BSA-ENRO binding.....41

LISTA DE TABELAS

Capítulo 1

Table 1. Plot of variation of the standard molar enthalpy change (ΔH°) versus temperature for the BSA-ENRO binding.....	10
Table 2. Kinetic rate constants for the association (k_a) and dissociation (k_d) of bovine lactoferrin-curcumin complex at pH 7.4.....	13
Table 3. Binding constants (K_b) and thermodynamic parameters (ΔG° , ΔH° , and $T\Delta S^\circ$) of interaction and standard heat capacity change (ΔC_p°) between bLF and CUR at pH 7.4 and different temperatures.....	15

Capítulo 2

Table 1. The binding constant (K_b), standard enthalpy change (ΔH°), standard Gibbs free energy change (ΔG°) and standard entropy change ($T\Delta S^\circ$) associated to formation of ENRO-BSA complex at pH = 7.4.....	35
---	----

RESUMO

LELIS, Carini Aparecida, D.Sc., Universidade Federal de Viçosa, fevereiro de 2019. **Interações intermoleculares entre proteínas do leite e moléculas de interesse na área de alimentos.** Orientadora: Ana Clarissa dos Santos Pires. Coorientadores: Luis Henrique Mendes da Silva e Nélio José de Andrade.

As proteínas do leite têm sido alvo de estudos como estruturas para veiculação de pequenas moléculas como, drogas lícitas, compostos bioativos, corantes, etc. Estas proteínas apresentam em sua estrutura sítios capazes de interagir com compostos hidrofóbicos e assim veiculá-los. A ENRO é um antibiótico utilizado no tratamento de vacas com mastite e, quando boas práticas agropecuárias não são realizadas, resíduos de antibióticos são encontrados no leite. A CUR é um corante natural, utilizado na indústria de alimentos, que apresenta propriedades bioativas. Várias moléculas, inclusive proteínas, tem sido estudado para interagir com a CUR e assim transportá-la. No entanto, não há estudos na literatura propondo a bLF como molécula de transporte para a CUR. O presente trabalho teve como objetivo estudar a nível molecular os mecanismos envolvidos na interação entre: curcumina (CUR) e lactoferrina (bLF) e, enrofloxacina (ENRO) e albumina do soro bovino (BSA), em diferentes condições de temperatura e em pH fisiológico. Para o estudo de interação entre bLF e CUR foram utilizadas técnicas sensíveis e eficazes como fluorescência e a ressonância plasmônica de superfície (SPR). No estudo de interação entre BSA e ENRO foi utilizado a espectroscopia de fluorescência. Resultados de fluorescência mostraram que a intensidade de fluorescência da bLF diminuiu à medida que as concentrações de CUR aumentaram. O mecanismo de extinção da fluorescência foi classificado como estático, havendo portanto, a formação de complexos entre bLF e CUR nas condições termodinâmicas estudadas. Além disso, a variação de energia livre de Gibbs de formação de complexo foi negativa, sendo regida pela entropia. A análise de SPR também demonstrou a ocorrência de formação de complexos entre bLF e CUR. No entanto, em baixas temperaturas (285.15 K a 293.15 K) o processo foi regido pela entropia, já em temperaturas maiores (297.15 K a 301.15 K) foi regido pela entalpia. Adicionalmente, verificou-se que as novas interações formadas com a formação do complexo apresentaram menor capacidade de transferência de energia nas formas potencial do que quando as moléculas estavam livres. O estudo cinético de

formação de complexo entre bLF e CUR mostrou que a energia de ativação para a associação e dissociação do complexo (bLF-CUR) aumentou com o aumento da temperatura. Em baixas temperaturas, CUR demonstrou interagir preferencialmente na superfície da bLF, já em temperaturas mais elevadas a CUR se insere no interior da proteína. Também foi verificado a ocorrência do fenômeno de compensação entalpia-entropia, estando relacionado principalmente a dessolvatação e a mudanças conformacionais no local de interação. Para o estudo de interação entre BSA e ENRO, foi utilizado a espectroscopia de fluorescência, baseando-se na capacidade da ENRO em emitir fluorescência. No estudo verificou-se que ENRO se ligar preferencialmente no subdomínio IIA (sitio I) da BSA, sendo o processo de interação exotérmico. O complexo formado demonstrou ser mais estável em baixas temperaturas. Também foi verificado que no processo de formação do complexo BSA-ENRO houve a compensação entálpico-entropico e, as novas interações formadas com a formação do complexo (BSA-ENRO) apresentaram maior capacidade de transferência de energia para as formas potenciais que as interações que ocorrem quando as moléculas estão livres, ao contrário do que foi observado para bLF e CUR. Este estudo contribui para o conhecimento em nível molecular da interação entre proteínas do leite e moléculas de interesse na área de alimentos, em diferentes condições de temperatura e pH fisiológico, sendo um guia útil para a otimização da utilização de proteínas do soro como carreadoras.

ABSTRACT

LELIS, Carini Aparecida, D.Sc., Universidade Federal de Viçosa, February, 2019. **Intermolecular interactions between milk proteins and molecules of interest in the food area.** Adviser: Ana Clarissa dos Santos Pires. Co-advisers: Luis Henrique Mendes da Silva and Nélio José de Andrade.

Milk proteins have been studied for the transport of small molecules, such as pharmaceuticals, bioactive compounds, dyes, etc. These proteins have in their structure sites capable of interacting with hydrophobic compounds and thus carry them. The objective of this study was to study the molecular mechanisms involved in the interaction between curcumin (CUR) (bioactive compound) and lactoferrin (bLF) and enrofloxacin (ENRO) and bovine serum albumin (antibiotic used in the treatment of cows with mastitis) under different temperature conditions and at physiological pH. For the interaction study between bLF and CUR, sensitive and efficient techniques were used, such as fluorescence and surface plasmon resonance (SPR). Fluorescence results showed that the fluorescence intensity of bLF decreased with increasing concentrations of CUR. The fluorescence quenching mechanism was classified as static, showing the occurrence of complex formation between bLF and CUR under the thermodynamic conditions studied. In addition, the Gibbs free energy variation of the complexation was negative, being governed by entropy. SPR analysis also demonstrated the occurrence of complex formation between bLF and CUR. However, at low temperatures (285.15 K to 293.15 K) the process was governed by entropy, and at higher temperatures (297.15 K at 301.15 K) was governed by enthalpy. In addition, it was found that the complex formed had lower energy transfer capacity in the potential forms than the free molecules. The kinetic study of complex formation between bLF and CUR showed that the activation energy for association and dissociation of the complex (bLF-CUR) increased with increasing temperature. At low temperatures, the CUR showed to interact preferentially on the surface of the bLF, already at higher temperatures, the CUR penetrates inside the protein. It was also verified the occurrence of the enthalpy-entropy compensation phenomenon, namely related to the desolvation and to the conformational changes in the interaction site. for the interaction study between BSA and ENRO, fluorescence spectroscopy was used, based on ENRO's ability to emit fluorescence. In the study verified that the mechanism of

extinction of the fluorescence was static, occurring the formation of BSA-ENRO complex. ENRO demonstrated to bind preferentially to the subdomain IIA (site I) of the BSA, the interaction process being exothermic. the complex has been shown to be more stable at low temperatures. It was also verified that in the process of formation of the BSA-ENRO complex there was the enthalpy-entropic compensation and the formed complex (BSA-ENRO) presented greater capacity of transference of energy to the potential forms than the free molecules, unlike which was observed for bLF and CUR. This study contributes to the knowledge, at the molecular level, of the interaction between milk proteins and molecules of interest in the food area under different temperature conditions and physiological pH, being a useful guide for the optimization of the use of whey proteins as carriers.

INTRODUÇÃO GERAL

O leite bovino contém cerca de 3,5% (m/m) de proteínas que, além de fornecerem aminoácidos, são veículos naturais de micronutrientes essenciais, assim como componentes do sistema imune. As proteínas encontradas no leite são moléculas de custo relativamente baixo, alta disponibilidade, são reconhecidas como seguras, apresentam alto valor nutricional e são capazes de interagir com pequenas moléculas, principalmente moléculas hidrofóbicas, e assim veiculá-las. Essas características tem despertado o interesse da indústria de alimentos e farmacêutica para a utilização dessas proteínas no transporte de diversas moléculas.

As proteínas do leite são divididas em duas frações principais, as caseínas e as proteínas do soro. As proteínas do soro constituem um grupo bastante diversificados de proteínas com características estruturais e funcionais bem diferentes. Entre as proteínas do soro pode-se destacar a albumina do soro bovino (BSA) e a lactoferrina. A BSA é o principal transportador das mais variadas moléculas no organismo, seja moléculas de caráter hidrofóbico ou hidrofílico. A lactoferrina é uma proteína que apresenta em sua estrutura íons de ferro ligados, e apresentam várias funções fisiológicas importantes. Essas proteínas apresentam vários sítios de ligação com diferentes afinidades, podendo atuar no transporte de diferentes moléculas.

Ao interagir com pequenas moléculas, chamadas de ligantes, as proteínas do soro podem aumentar a solubilidade dos ligantes hidrofóbicos em meios aquosos, aumentar a biodisponibilidade, modular a entrega de drogas e compostos bioativos no organismo, além de proteger essas moléculas frente a condições do meio como, temperatura, luz, oxigênio, etc.

A CUR é um composto bioativo em que sua utilização em alimentos é limitada, uma vez que este bioativo é solúvel em óleo, apresenta pouca estabilidade contra o calor, luz e oxigênio, bem como baixa solubilidade. Dessa forma, sua aplicação em soluções aquosas possui baixa viabilidade técnica. A ENRO, um antibiótico utilizado no tratamento de animais com mastite, também é uma molécula com baixa solubilidade e molhabilidade em água, o que leva a dificuldades no desenvolvimento de formulações farmacêuticas.

A determinação dos parâmetros termodinâmicos e cinéticos de interação entre proteínas do soro e compostos de interesse (tipos de interações, estequiometria de formação do complexo, constante de interação, sítios de interação, constante cinética de associação e dissociação, energia de ativação do complexo ativado, capacidade calorífica, etc) é essencial para o melhor entendimento dos mecanismos de interação,

que são úteis para que as indústrias possam melhorar o desenvolvimento de sistemas de entrega.

Diante disso, a realização de pesquisas que visam entender as interações entre as proteínas do soro e moléculas de interesse pode contribuir para otimizar o transporte das mesmas. O transporte de drogas no sangue, assim como sua liberação, é de extrema importância do ponto de vista da farmacocinética. Já nos alimentos, o transporte de moléculas como os compostos bioativos pode melhorar as características sensoriais dos alimentos, manter propriedades funcionais e otimizar a utilização destes compostos. Com isso, o objetivo do nosso trabalho foi estudar a interação entre proteínas do soro de leite (bLF e BSA) e compostos de interesse na área de alimentos (CUR e ENRO), fornecendo informações úteis para a otimização da utilização dessa proteínas no transporte de moléculas como CUR e ENRO.

1 **Capítulo 1: Lactoferrin-curcumin binding: a thermodynamic, and kinetic study of**
2 **an important biofunctional complex**
3

4 **Abstract**
5

6 An understanding of the thermodynamics and kinetics of the interaction between
7 bovine lactoferrin (bLF) and curcumin (CUR) is needed for the application of this
8 system to food and pharmaceutical formulations. We used fluorescence spectroscopy
9 (FS) and surface plasmon resonance (SPR) to study the formation of the bLF-CUR
10 complex. The fluorescence spectroscopy results showed positive values of standard
11 enthalpy and entropy changes ($\Delta H^\circ = 66.5 \text{ kJ}\cdot\text{mol}^{-1}$ and $T\Delta S^\circ = 90.7$ to $94.7 \text{ kJ}\cdot\text{mol}^{-1}$),
12 indicating that hydrophobic interactions are the main forces contributing to bLF-CUR
13 binding. The ΔH° values obtained by SPR were lower ($\Delta H^\circ = 42.83$ to $-35.86 \text{ kJ}\cdot\text{mol}^{-1}$),
14 suggesting that the interactions that occur far from the Trp residues release more
15 energy. ΔC_p° value was negative, indicating that the bLF-CUR complex has less ability
16 to transfer heat energy to the potential form than the free bLF and CUR molecules.
17 Through the energy parameters it was possible to propose that at low temperature
18 CUR interacted at bLF interface, however with the increase in the temperature the
19 bioactive molecule penetrates into the inner of the protein. In both studies of
20 thermodynamic and kinetics parameters obtained by SPR, the occurrence of the
21 enthalpy-entropy compensation (EEC) phenomenon was verified. Thus, this work show
22 a complete thermodynamic and kinetic characterization of the formation of the bLF-
23 CUR complex, providing important information for technological applications of this
24 important biofunctional complex.

25

26 **Keywords:** lactoferrin; curcumin; fluorescence; surface plasmon resonance

27

28 **1. Introduction**

29 Bovine lactoferrin (bLF) is a member of the transferrin family and is composed of
30 692 amino acids folded into two homologous globular lobes connected by turn helix
31 and each lobe is formed by two domains connected by Fe³⁺ ions. bLF is found in cow
32 milk, mucosal secretions, tears, saliva, blood (Croguennec, Li, Phelebon, Garnier-
33 Lambrouin, & Gésan-Guiziou, 2012; Farnaud & Evans, 2003) and exhibits many
34 important biological functions as an antioxidant, anticancer agent, and carrier of iron
35 and different bioactive compounds ^{1,6-9}. Because of these properties, bLF has been
36 increasingly used in different food products (Bokkhim et al., 2015), such as fortified
37 yoghurts, infant formulae, and dietary supplements (Wakabayashi et al., 2006; Tomita
38 et al., 2009). It has been intensively studied, and these studies have shown that bLF
39 has potential to carry different bioactive compounds in food, as for exemple: (-)-
40 epigallocatechin-3-gallate (EGCG) (Yang et al., 2014) and rosmarinic acid (Ferraro et
41 al., 2015).

42 As example of bioactive compounds is curcumin (CUR), also known as
43 diferuloylmethane ¹⁵, ¹⁵ is a hydrophobic polyphenol extracted from
44 turmeric. Studies have shown that CUR has potential as an antioxidant ^{5,16}, anti-
45 inflammatory and antitumor ^{4,17,18}, as well as being a regulator of many biological
46 processes ¹⁹. However, CUR is almost insoluble in water (solubility = 0.6 µg/mL)²⁰ at
47 acidic and neutral pH, which limits its bioavailability (Maiti et al., 2007; Wang et al.,
48 2008). Moreover, CUR is sensitive to oxygen, light, and high temperatures ²³.

49 Aiming to overcome these limitations, researchers have investigated different
50 carriers for CUR. For example, Mangolim et al. (2014) showed important evidence of
51 CUR-β-cyclodextrin (β-CD) inclusion complex formation. The occurrence of the
52 interaction between CUR and β-CD intensified the color of the vanilla ice cream and
53 produced a great sensory acceptance. Camel β-casein micelles demonstrated interact
54 with CUR mainly via hydrophobic interactions, with a binding constant of 1.8 x 10⁴ M⁻¹,
55 at 298 K ²⁵. The complex formed between CUR and bovine serum albumin (BSA)
56 analyzed by isothermal titration microcalorimetry, showed a binding constant of the

57 order of 10^5 M^{-1} , and the formation of the complex was entropically driven²⁶. Thus, due
58 to the presence of hydrophobic regions in their structure^{27,28}, the bLF may be a
59 promising nanovehicle for CUR (Bollimpelli et al., 2016). However, there are no studies
60 concerning the kinetics and thermodynamics of the interaction between bLF and CUR.
61 Understanding the kinetics and thermodynamics of bLF-CUR binding is strategic
62 because it can provide relevant information about the energetic e molecular dynamics
63 of interaction between these molecules, enabling optimize their use in food products.

64 Fluorescence spectroscopy (FS) is one of the most used techniques to investigate
65 the thermodynamic of protein–ligand binding because it is sensitivite, selective and
66 rapid (Atrahimovich, et al. 2012). In addition, bLF presents in its structure 13 residues
67 of tryptophan, which makes FS analysis strategic for the interaction study (Steijns and
68 van Hooijdonk, 2000). However, for a more complete understanding of the dynamic
69 processes of interaction between bLF and CUR, beyond to the thermodynamic
70 parameters, a kinetic study of the interaction is required. Surface plasmon resonance
71 (SPR) is a strategic technique able to analyze interaction between protein and analytes
72 in a fast, sensitive and label-free way, detecting, at real-time, the binding events (Atale,
73 Dyawanapelly, Jagtap, Jain, & Dandekar, 2019; Gombau et al., 2019; Schasfoort &
74 Tudos, 2013). With the SPR, it is possible to determine thermodynamic and kinetic
75 binding parameters in a single set of experiments.

76 Based on the potential of CUR and bLF as biofunctional compounds for food
77 applications, this will be the first study to provide us with data on the thermodynamics
78 and kinetics of interaction between bLF and CUR, thus helping to optimize the use of
79 bLF as a carrier of CUR.

80

81 **2. Material and Methods**

82 **2.1. Materials**

83 Lactoferrin (>97% wt.), CUR (80% wt.), dibasic sodium phosphate (NaHPO₄),
84 monohydrated sodium phosphate (NaH₂PO₄·H₂O), of analytical grade, were purchased
85 from Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO, C₂H₆OS), of
86 analytical grade, was purchased from Neon Commercial Ltda (São Paulo, SP, Brazil).
87 3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide (EDC) (> 99% wt), N-
88 hydroxysuccinimide (NHS) (> 99% wt), sodium acetato (> 99% wt) and
89 ethanolaminehydrochloride were purchased from General Electric Healthcare
90 Company, (Sweden).

91 **2.2. Fluorescence Experiments**

92 Fluorescence spectra were obtained with an LS-55 spectrofluorimeter (Perkin-
93 Elmer, USA) equipped with quartz cells (1.0 cm) and a thermostatic bath. Initially a
94 solution of CUR 5×10^{-3} mol·L⁻¹ in DMSO was prepared. From this solution was
95 prepared the stock solution of CUR 1×10^{-4} mol·L⁻¹, in solution of bLF 3×10^{-6} mol·L⁻¹.
96 For fluorescence measurements, 10 titrations of 50 µL of a stock solution of CUR (2.5
97 to 25 µM) in 2.0 mL of bLF solution (3.0×10^{-6} mol·L⁻¹) in a quartz cell and at pH 7.4
98 were used ³⁴. To minimize the effect of 10 titrations of CUR containing DMSO on the
99 intrinsic protein fluorescence, we added 2% DMSO to the bLF solution in a quartz $3.0 \times$
100 10^{-6} mol·L⁻¹cell. bLF was excited at 295 nm and fluorescence emission spectra were
101 then measured in the wavelength range of 296 to 450 nm, at five different temperatures
102 (293.15, 296.15, 299.15, 303.15 e 306.15 K)

103 **2.3. SPR experiments**

104 The kinetics and thermodynamics of interaction between bLF and CUR were
105 explored by SPR (Biocore X100 – GE Healthcare, Pittsburgh, PA, USA). Before
106 analysis, bLF was immobilized on the CM5 sensor chip using a Biocore amine coupling

107 kit, according to the manufacturer's instructions. The carboxylic groups, formed when
108 the sensor chip is docked in the instrument, was activated for 7 min with a 1:1 mixture
109 of 0.1 mol.L⁻¹ 3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide (EDC) and 0.1 mol.L⁻¹
110 N-hydroxysuccinimide (NHS) at a flow rate of 20 μL.min⁻¹ and at 298 K. Then, a
111 solution at 3.0 × 10⁻⁶ mol.L⁻¹ of bLF in 10 mmol.L⁻¹ of sodium acetate at pH 7.0 was
112 injected for 7 min, resulting in a lower density bLF immobilization. A 7 min pulse of
113 1 mol L⁻¹ ethanolaminehydrochloride, pH 8.5, was then injected to deactivate the
114 excess hydroxysuccinimidyl groups on the surface that did not reacted with the protein.

115 The bLF-CUR binding experiments were carried out at pH 7.4 and temperatures
116 that ranged from 285.15 to 301.15 K. The concentrations of the CUR solutions (30–
117 100 μM) were prepared in flowing buffer sodium phosphate. In each binding
118 experiment, the CUR solution at the required concentration was injected in order to
119 increase colorant concentration over both sample (with immobilized bLF) and reference
120 (without bLF) surfaces. The two-channel injection (sample and reference) was
121 performed to correct for systematic noise and instrument drift. Between each bLF-CUR
122 binding cycle, buffer was injected to determine the baseline.

123 The bLF image used to make a hypothetical description of the interaction sites
124 of CUR for bLF were extracted from the Protein Data Bank (PDB ID: 1blf) (2.8
125 angstroms resolution) (<http://www.pdb.org/pdb/home/home.do>).


126 All experiments were carried out in triplicate and the relative errors were between 1
127 and 3 %. The results were expressed as mean ± standard deviation.

128 **3. Results and Discussion**

129 **3.1. Fluorescence Measurements**

130 Many proteins exhibits fluorescence mainly due to the Trp and Tyr residues³⁵. The
131 bLF has 13 Trp residues (Trp-8, Trp-16, Trp-22, Trp-24, Trp-125, Trp-138, Trp-268,
132 Trp-347, Trp-361, Trp-448, Trp-467, Trp-549, and Trp-560) (Steijns and van Hooijdonk,
133 2000), which are accountable for the intrinsic fluorescence emission of the protein. The

134 binding between bLF and small molecules, such as CUR can quench bLF
 135 fluorescence. When it was excited at 295 nm, the resultant fluorescence maximum
 136 emission peak was about 335 nm (Figure 1). The addition of increasing CUR
 137 concentrations reduced the protein fluorescence intensity by 54%, indicating change
 138 around the region of tryptophan residues, which may be due to complex formation
 139 between bLF and CUR.



140

141 Figure 1. Fluorescence emission spectra of 3.0 μM bLF in the presence of 0, 2.5, 5.0,
 142 7.5, 10.0, 12.5, 15.0, 17.5, 20.0, 22.5, 25.0 μM CURC at pH 7.4.

143

144 The fluorescence quenching data were studied using the Stern–Volmer equation
 145 (Eq. 1).

146

$$147 \quad \frac{F_0}{F} = 1 + K_{sv} [Q] = 1 + K_q \tau_0 [Q] \quad (1)$$

148

149 Here, F_0 and F are the fluorescence intensities of fluorophore before and after the
 150 addition of the quencher (CUR), respectively, $[Q]$ is the quencher concentration ($\text{mol}\cdot\text{L}^{-1}$)
 151 ¹), K_{sv} is the Stern-Volmer quenching constant, τ_0 is the average protein fluorescence
 152 lifetime in the absence of the quencher, and K_q is the biomolecular quenching constant.
 153 From the fluorescence intensities, it was possible to determine the values of K_{sv} by
 154 linear regression (F_0/F vs. $[Q]$).

155 The K_q values were found to be at least 50 times higher than the K_q values for
 156 biomolecules, i.e., $1.00 \times 10^{10} \text{ L}\cdot\text{mol}^{-1}\cdot\text{s}^{-1}$ ³⁶. This magnitude of K_q indicates that the

157 main fluorescence quenching mechanism is static, arising from complex formation
158 between bLF and CUR (Silva *et al.*, 2017; Lelis *et al.*, 2017; Nunes *et al.*, 2017).


159 After the confirmation that the fluorescence quenching mechanism is
160 predominantly static and assuming that the binding sites of the protein (bLF) for CUR
161 are independent and with similar binding constants, the equilibrium between the free
162 and bound CUR molecules at the bLF sites is given by the Stern–Volmer equation (Eq.
163 2).

$$164 \quad \log\left(\frac{F_0-F}{F}\right) = \log K_b + n \log[Q_t] \quad (2)$$

165

166 Here, F_0 and F are the fluorescence intensities of bLF in the absence and the presence
167 of CUR respectively, n is the number of binding sites, K_b is the binding constant, and
168 $[Q_t]$ is the total CUR concentration.

169 The stoichiometry (n) and the binding constant (K_b) for complex formation were
170 calculated applying the Eq. 2 to double logarithmic plot between $\log [(F_0 - F)/F]$ vs. \log
171 $[Q]$ at five temperatures (Figure 2, Table 1). The n and K_b values were extracted from
172 intercept and slope of this curve, respectively.



173

174 Figure 2. The plot of $\log[(F_0-F)/F]$ as a function of $\log [Q]$, being binding constant (K_b)
175 the intercept and stoichiometry (n) the slope at pH 7.4.

176

177 The K_b values ranged from 2.07 a $6.68 \times 10^4 \text{ L}\cdot\text{mol}^{-1}$, increasing about 3.3 times
 178 with increasing temperature, which indicates that the bLF-CUR complex is more stable
 179 at higher temperatures. The n values were close to 1 at all temperatures, suggesting
 180 that each available Trp site in bLF can interact with one CUR molecule. Other studies
 181 have found similar stoichiometries for CUR binding with different serum proteins, such
 182 as BSA ²⁶, human serum albumin (HSA) (Ge *et al.*, 2014), α -lactoalbumin (α -la)
 183 (Mohammadi and Moeeni, 2015), and β -lactoglobulin (β -lg) (Mohammadi *et al.*, 2009).
 184 However, BSA, HSA, α -la, and β -lg contain 2, 1, 4 and 2 Trp residues, respectively,
 185 whereas bLF has 13 Trp residues, indicating that this protein can bind up to 13 CUR
 186 molecules, if all of Trp sites are available for interaction. This result provides important
 187 insights about the potential of bLF as a carrier for hydrophobic bioactive molecules.

188 The protein–ligand binding may consist of different interactions such as hydrogen
 189 bonds, electrostatic, hydrophobic, and van der Waals. To further elucidate the
 190 interactions between bLF and CUR, the thermodynamic parameters of complex
 191 formation (ΔG° , ΔH° , and $T\Delta S^\circ$), were calculated following the approach: The standard
 192 Gibbs free energy change (ΔG°) values were directly calculated from the K_b values at
 193 each temperature (Eq. 3); the standard enthalpy change (ΔH°) value was determined
 194 by following the van't Hoff approach (Eq. 4) by the plotting of $\ln K_b$ versus $1/T$, and the
 195 standard entropy change ($T\Delta S^\circ$) was obtained using the fundamental Gibbs equation
 196 (Eq. 5), listed in Table 1.

197

198

$$199 \quad \Delta G^\circ = -RT \ln K_b \quad (3)$$

200

$$201 \quad \frac{\ln K_{b2}}{\ln K_{b1}} = - \frac{\Delta H^\circ}{R} \left(\frac{1}{T_2} - \frac{1}{T_1} \right) \quad (4)$$

202

$$203 \quad T\Delta S^\circ = \Delta H^\circ - \Delta G^\circ \quad (5)$$

204

205 Here, R is the universal gas constant ($8.3145 \text{ J}\cdot\text{mol}^{-1}\cdot\text{K}^{-1}$), T is the temperature (K),
 206 and K is the binding constant ($\text{L}\cdot\text{mol}^{-1}$).

207 Table 1. Binding constants (K_b), the number of binding sites (n) and thermodynamic
 208 parameters of interaction between bLF and CUR at pH 7.4 at different temperatures.

T(K)	K_b^a	n	$\Delta G^\circ{}^b$	$\Delta H^\circ{}^b$	$T\Delta S^\circ{}^b$
293.15	2.07 ± 0.18	0.94 ± 0.18	-24.2		90.7
296.15	2.60 ± 0.19	0.96 ± 0.19	-25.0		91.5
299.15	3.01 ± 0.16	1.03 ± 0.16	-25.6	66.5	92.1
303.15	4.72 ± 0.32	1.01 ± 0.32	-27.1		93.6
306.15	6.68 ± 0.35	1.05 ± 0.35	-28.2		94.7

209 The superscript letters represents the units: ^a ($10^4 \text{ L}\cdot\text{mol}^{-1}$) ^b($\text{kJ}\cdot\text{mol}^{-1}$); $R^2 = 0.99$

210

211 The ΔG° values were found to be negative, indicating that the chemical equilibrium
 212 favored the formation of the bLF-CUR complex. The positive ΔH° and $T\Delta S^\circ$ values
 213 indicate that the complex formation process was endothermic, being driven by the
 214 entropy increase, probably because of the hydrophobic interactions between bLF and
 215 CUR⁴². CUR has in its chemical structure hydrophobic groups such as benzene rings,
 216 which may interact with the hydrophobic side chains of the protein. Further, the release
 217 of water molecules from the solvation layer of both interacting molecules (bLF and
 218 CUR) resulted in an increase in the system entropy.

219 The enthalpic contribution (ΔH°) to bLF-CUR binding could be rationalized as a
 220 result of three molecular processes, i.e., desolvation of the bLF and CUR surfaces
 221 (ΔH_{des}), conformational change of the bLF interaction site ($\Delta H_{mud.conf}$), and the
 222 formation of the bLF-CUR interactions ($\Delta H_{bLF-CURC}$) (Eq. 6). The positive values of ΔH°
 223 show that the contribution of the endothermic processes, desolvation and denaturation,
 224 is higher than the process of the formation of the bLF-CUR interaction. Thus, the
 225 energy absorption process for the conformational change of the interaction site and the

226 release of water molecules from the solvating layer of bLF and CUR contributed more
227 during the formation of the bLF-CUR complex.


228
$$\Delta H^0 = \Delta H_{des} + \Delta H_{mud.conf} + \Delta H_{bLF-CUR} \quad (6)$$

229 **3.2. SPR results**

230 While fluorescence spectroscopy is limited to analyze interactions, which occur
231 close to the Trp residues on bLF, the SPR may be used as broader technique to
232 explore bLF-CUR interaction. In addition, SPR allow us to obtain kinetic parameters
233 associated to the formation of the bLF-CUR complex. These kinetic parameters are
234 important because they can complement the thermodynamic data, providing
235 information about the rate of complex association and dissociation⁴³.

236 In the sensogram obtained with the SPR (Figure 3) there are two main distinct
237 regions in the sensorgram: region A where occurs simultaneously the complex
238 association, and dissociation, prevailing the association process and region D, where
239 the process of dissociation prevails.

240



241

242 Figure 3. Sensograms (RU vs. time) for bovine lactoferrin -curcumin binding at 298 K
243 and pH 7.4. The arrows indicates increasing CUR concentration (30-100 μM).

244

245 When the CUR solution flowed over the chip surface with immobilized-bLF, the
 246 resonance signal (resonance units - RU) along the time changed. From this it is
 247 possible to determine the kinetic rate constant of dissociation (k_d), adjusting the data
 248 of the sensor to Eq. 7.

$$249 \quad RU(t) = RU(t_m) e^{-k_d(t-t_m)} \quad (7)$$

250 where t_m is the time when dissociation process started and $RU(t_m)$ is resonance in t_m .

251

252 The kinetic rate constant of association (k_a) was determined fitting the sensorgram
 253 data to Eq. 8 and then using Eq. 9. The k_a is the slope of the k_{obs} vs. $[CUR]$ plot.

254

$$255 \quad RU(t) = RU_{max}(t_\infty)[1 - e^{-k_{obs}(t)}] \quad (8)$$

$$256 \quad k_{obs} = k_a[CUR] + k_d \quad (9)$$

257 where $[RU(t)]$ is the SPR signal obtained in the sensorgram at time t , k_{obs} is the
 258 observed constant, and $[RU_{max}(t_\infty)]$ is the SPR response at bLF saturation by CUR.

259 The k_a and k_d values are shown in Table 2.

260

261 Table 2. Kinetic rate constants for the association (k_a) and dissociation (k_d) of bovine
 262 lactoferrin-curcumin complex at pH 7.4.


T (K)	k_a ($10^3 \text{ M}^{-1}\text{s}^{-1}$)	k_d (s^{-1})
285.15	1.23±0.06	0.31±0.01
289.15	1.23±0.05	0.26±0.01
293.15	1.27±0.07	0.24±0.01
297.15	1.37±0.09	0.25±0.01
298.15	1.46±0.10	0.27±0.01
301.15	1.70±0.12	0.37±0.01

263

264 The k_a and k_d values were of the order of $10^3 \text{ M}^{-1}\text{s}^{-1}$ and 10^{-1} s^{-1} , respectively,
 265 and they showed a second order polynomial dependence on temperature (Figure S1).

266 Initially the values of k_a decreased and from 289 K increased. The same was observed

267 for k_d , with a minimum point at 292.5 K. This non-linear behavior indicates that both
 268 association of bLF and CUR to form bLF-CUR complex as well as its dissociation
 269 occurred in a multi-step process, involving conformational change of the protein.
 270 Moreover, the different behavior of k_a and k_d with temperature shows that the
 271 dissociation process is not reversible to the association, that is, changes occurring
 272 during the association to form the complex, are not completely undone by the
 273 dissociation of the complex and/or new changes during dissociation may occur.
 274



275

276 Figure S1 – Plots of k_a (■) and k_d (○) versus T for bLF-CUR interaction at pH 7.4.
 277 Polynomial equation for association process:
 278 $k_a = 0.003 (T)^2 - 1.89 (T) + 274.40$; $R^2 = 0.96$ and for dissociation process: $k_d =$
 279 $0.001 (T)^2 - 0.98 (T) + 143.72$; $R^2 = 0.86$.
 280

281 Hudson et al. (2018) found k_a and k_d values 10- and 2-fold higher, respectively,
 282 than those found by us for CUR interacting with BSA at pH 7.4 and 298.15 K ($1.49 \times$
 283 $10^4 \text{ M}^{-1}\text{s}^{-1}$ and $6.77 \times 10^{-1} \text{ s}^{-1}$) than those found for bLF-CUR. This difference can be
 284 related to the protein structure, size, and conformational changes induced by the
 285 interaction with CUR (Guo, Lu, Wang, & Brodelius, 2017).

286 The relationship between the kinetic rate constants yields the thermodynamic
 287 binding constant ($K_b = k_a/k_d$). Therefore, using the SPR kinetic experiment, the

288 thermodynamic parameters were also obtained (Eqs. 3-5), and they are presented in
 289 Table 3.

290 Table 3 Binding constants (K_b) and thermodynamic parameters (ΔG° , ΔH° , and $T\Delta S^\circ$)
 291 of interaction and standard heat capacity change (ΔC_p°) between bLF and CUR at pH
 292 7.4 and different temperatures.

T (K)	k_b^a	ΔG°^b	ΔH°^b	$T\Delta S^\circ^b$	$\Delta C_p^\circ^c$
285.15	3.97±0.16	-19.65±0.79	42.83±1.71	62.48±2.50	
289.15	4.71±0.23	-20.33±1.02	22.34±1.12	42.68±2.13	
293.15	5.30±0.16	-20.90±0.63	2.42±0.07	23.31±0.70	
297.15	5.48±0.28	-21.27±1.06	-16.98±0.04	4.29±0.21	-4.92
298.15	3.39±0.20	-21.30±1.28	-21.75±1.31	-0.45±0.03	
301.15	4.59±0.18	-21.11±0.84	-35.86±1.43	-14.75±0.59	

293 The superscript letters represents the units: ^a ($10^3 \text{ L}\cdot\text{mol}^{-1}$), ^b ($\text{KJ}\cdot\text{mol}^{-1}$) and ^c ($\text{KJ}\cdot\text{K}^{-1}\cdot\text{mol}^{-1}$); $R^2 = 0.99$
 294

295

296 The K_b values of bLF-CUR binding obtained by SPR ($K_{b\text{-SPR}}$) were of the order
 297 of 10^3 M^{-1} , showing to be 10 times lower than the K_b values found by fluorescence ($K_{b\text{-FS}}$).
 298 The K_b value is the product of the binding constants of each binding site for CUR in
 299 the protein ($K_b = K_{b1} \cdot K_{b2} \cdot \dots \cdot K_{bn}$); thus, the SPR analysis detected all the available
 300 sites for in bLF interaction with CUR, including those not counted by FS, and these
 301 sites show lower K_b values, thus contributing to the reduce $K_{b\text{-SPR}}$ values.

302 Both techniques showed that when CUR interacts with bLF the ΔG° values
 303 were similar, $-24.2 \text{ kJ}\cdot\text{mol}^{-1}$ and $-20.90 \text{ kJ}\cdot\text{mol}^{-1}$ for FS and SPR, respectively, at 293.15
 304 K. However, the values of ΔH° and $T\Delta S^\circ$ did not show exactly the same behavior in
 305 both techniques. For SPR, van 'Hoff approach showed a second order polynomial
 306 dependence of ΔH° in relation to the inverse of the temperature. The $\Delta H^\circ_{\text{SPR}}$ values
 307 show that the process of interaction between bLF and CUR at low temperatures was
 308 endothermic, becoming exothermic with the increase in the temperature. The Eq. 6 can
 309 also be applied to evaluate the $\Delta H^\circ_{\text{SPR}}$ values. At lower temperature, the $\Delta H^\circ_{\text{SPR}}$ values


310 is positive because $|\Delta H_{\text{des}} + \Delta H_{\text{ccs}}| > |\Delta H_{\text{bLF-CUR}}|$. The CUR when interacting with the bLF
311 can cause conformational changes in the protein, contributing to the positive values of
312 ΔH° . In addition, when compared to higher temperatures, at lower temperature the
313 water molecules are more structured around the hydrophobic regions the bLF e CUR,
314 which demands more energy for desolvation. On the other hand, with the increase of
315 the temperature, the water molecules are more unstructured, being $|\Delta H_{\text{bLF-CUR}}| > |\Delta H_{\text{des}}$
316 $+ \Delta H_{\text{ccs}}|$ and therefore, the ΔH° values are negative.

317 By FS the behavior of van't Hoff approach was linear, thus obtaining only a
318 value for ΔH° in the studied temperature rang. In addition, it was verified that the $\Delta H^\circ_{\text{FS}}$
319 was higher than the $\Delta H^\circ_{\text{SPR}}$. The $\Delta H^\circ_{\text{SPR}}$ values are the sum of the energies absorbed
320 and released at each interaction site. Thus, the values obtained by SPR suggest that
321 the interactions that occur far from the Trp residues release more energy, contributing
322 to lower values of $\Delta H^\circ_{\text{SPR}}$ when compared to the $\Delta H^\circ_{\text{FS}}$ value.

323 The same behavior was observed for $T\Delta S^\circ$. At low temperatures, the $T\Delta S^\circ$
324 values were higher when compared to the higher temperatures. The $T\Delta S^\circ$ values are
325 contributions of the configurational entropy change (ΔS_{conf}) due to the reduction of the
326 degrees of freedom of the complex formed from the free molecules and the desolvation
327 entropy change (ΔS_{des}), resulting from the release of water molecules from the layer of
328 solvation of both molecules (bLF and CUR). Hence, $\Delta S^\circ = \Delta S_{\text{des}} + \Delta S_{\text{conf}}$. The highest
329 $T\Delta S^\circ$ values show that at low temperature, $|\Delta S_{\text{des}}| > |\Delta S_{\text{conf}}|$, providing a greater
330 release of water molecules from the solvation shell of bLF and CUR when the complex
331 is formed. At higher temperatures $|\Delta S_{\text{conf}}| > |\Delta S_{\text{des}}|$ then water molecules are less
332 structured, and consequently the reduction of the degrees of freedom of the complex
333 formed from the free molecules has a greater contribution than the release of the water
334 molecules from the solvation layer.

335 The $T\Delta S^\circ$ values found by SPR (42.68 kJ mol⁻¹, 293.15 K) were lower than
336 those found by fluorescence (91.50 kJ mol⁻¹, 293.15 K). Probably processes such as
337 conformational changes and desolvation of the interaction sites identified by SPR are
338 different from the processes that occur in the interaction sites identified by the FS.

339 However, despite the remarkable variation of ΔH° and $T\Delta S^\circ$ as function of the
340 temperature, the ΔG° values showed a weak variation. This type of behavior suggest
341 the occurrence of the well known enthalpy–entropy compensation (EEC) ⁴⁴. To confirm
342 the occurrence of this phenomenon in our studies we plotted a plot of ΔH° vs $T\Delta S^\circ$
343 (Figure 4).




344

345 Figure 4: Enthalpy–entropy compensation plot of bLF-CUR binding.

346

347 The EEC phenomenon found in Figure 4 can be described by a increase in
348 enthalpy offset by a increase in entropy. A linear relationship was obtained with slope
349 and intercept (α and β) equal to 0.97 and 20.73, respectively. The slope near of unity
350 suggests that ΔH° are often compensated by $T\Delta S^\circ$ ⁴⁵, that is, ΔH° and $T\Delta S^\circ$ increase in
351 the same proportion. The increment of entropy may be attributed the release of water
352 from solvation layer of interacting molecules. However, this increase of entropy is
353 compensated by the energy absorption for the break of H₂O-H₂O interaction.

354 Through the dependence of ΔH° with the temperature, it was possible to
355 determine the standard heat capacity change, ΔC_p° , using the relation: $\Delta C_p^\circ = \left(\frac{\partial H^\circ}{\partial T}\right)_p$
356 (Figure 5) (Table 3).



357

358 Figure 5: Plot of variation of the standard molar enthalpy change (ΔH°) versus
 359 temperature for the bLF-CUR binding.

360

361 The heat capacity change values provide information about energy and
 362 structural modifications from the interaction. Considering that $\Delta C_p^o = C_{p-bLF-CUR}^o -$
 363 $(C_{p-bLF}^o + C_{p-CUR}^o)$, a negative ΔC_p^o indicates that the bLF-CUR complex has less
 364 ability to transfer heat energy from the surroundings to the molecular potential energy
 365 component than the free bLF and CUR molecules. During complex formation (bLF-
 366 CUR) some intramolecular interaction of free molecules are broken while some new
 367 intermolecular interactions are formed. Furthermore, it is known that the desolvation of
 368 water molecules from the surface of the protein and CUR results in negative values of
 369 ΔC_p^o ^{46,47}. This can be confirmed by the analysis of Tds values, which shows a
 370 contribution of the increase in the degree of freedom of the system due to the release
 371 of water molecules from the solvation layer.

372 3.2.1. Energetic parameters of formation of bLF-CUR activated complex

373 The dependence of k_a and k_d on the temperature change yields the
 374 determination of the kinetic energetic parameters related to the formation of an
 375 activated bLF-CUR complex, formed from the association of free bLF and CUR


376 molecules or from the dissociation of the thermodynamic stable bLF-CUR complex^{48,49}.
 377 These kinetic parameters are important because they provide information on potential
 378 energy and molecular dynamics changes associated with the activated complex
 379 formation.

380 Applying the Arrhenius approach of k_a and k_d on temperature (Figure S2), the
 381 activation energy for association of free bLF and CUR molecules ($E_{act(a)}$) and for
 382 dissociation of bLF-CUR thermodynamic stable complex ($E_{act(d)}$) to activated complex
 383 formation were obtained.

$$384 \quad E_{act(x)} = -R \frac{\partial \ln k_x}{\partial \frac{1}{T}} \quad (10)$$

385 In this equation, $E_{act(x)}$ is the activation energy for association or dissociation, R
 386 is the universal gas constant ($8.3145 \text{ J}\cdot\text{mol}^{-1}\cdot\text{K}^{-1}$), k_x is the kinetic rate constant of
 387 association ($\text{M}^{-1}\text{s}^{-1}$) or dissociation (s^{-1}) and T is the temperature (K).

388



389

390 Figure S2 - $\ln k_a$ (■) and $\ln k_d$ (○) versus the inverse of temperatures associated with
 391 the interaction between bovine lactoferrin and curcumin at a pH of 7.4. Polynomial
 392 equation for association process: $\ln k_a = 1.62 \times 10^7 (1/T)^2 - 1.12 \times 10^6 (1/T) +$
 393 201.58 ; $R^2 = 0.97$, and for dissociation process: $\ln k_d = 4.06 \times 10^7 (1/T)^2 - 2.78 \times$
 394 $10^6 (1/T) + 437.17$; $R^2 = 0.89$.

395

396 The kinetic enthalpy change (ΔH_x^\ddagger), the Gibbs free energy change (ΔG_x^\ddagger) and the
 397 entropic terms ($T\Delta S_x^\ddagger$) of association and dissociation phases to activated complex
 398 formation were calculated using the equations 11 to 13.

399

$$400 \quad \Delta H_x^\ddagger = E_{act(x)} - RT \quad (11)$$


$$401 \quad \Delta G_x^\ddagger(T) = -RT \ln(k_x h / K_B) \quad (12)$$

$$402 \quad T\Delta S_x^\ddagger = \Delta H_x^\ddagger - \Delta G_x^\ddagger \quad (13)$$

403

404 Here, R is the universal gas constant ($8.3145 \text{ J}\cdot\text{mol}^{-1}\cdot\text{K}^{-1}$), T is the temperature (K), h is
 405 the Planck constant ($6.626 \times 10^{-34} \text{ J}\cdot\text{s}$) and K_B is the Boltzmann's constant (1.38×10^{-23}
 406 $\text{ J}\cdot\text{K}^{-1}$).

407 The values of the kinetic parameters for the association and the dissociation
 408 phases are shown in Figure 6 (a) and (b), respectively.




409

410 Figure 6 – Plot of kinetic activation energetic parameters *versus* temperature: (Δ) E_{act} ,
 411 (\circ) ΔG^\ddagger , (\blacksquare) ΔH^\ddagger , and (\blacktriangle) $T\Delta S^\ddagger$ for (a) association and (b) dissociation phases.

412

413 The $E_{act(a)}$, ΔH_a^\ddagger , and $T\Delta S_a^\ddagger$ values showed an increasing second-order
 414 polynomial behavior as a function of temperature (Fig. 6), revealing that above 290 K
 415 these energetic parameters increased.

416 The formation of bLF-CUR activated complex is dependent on the following
 417 processes: i) bLF and CUR desolvation, ii) change in the bLF binding site
 418 conformation, and iii) bLF-CUR interaction, being only the last resulting in energy
 419 releasing. Therefore, it is reasonable to propose that at low temperatures CUR
 420 interacted at bLF interface; while small degree of desolvation and conformational site
 421 change however, with the increase in the temperature, the bioactive molecule
 422 penetrates into the inner of the protein, and thus there is desolvation of CUR and bLF-
 423 binding site and also change this binding site conformation, resulting in the increasing
 424 of $E_{act(a)}$, ΔH_a^\ddagger , and $T\Delta S_a^\ddagger$ values, s shown in the hypothetical figure below (Figure 7).



425

426 Figure 7 - The formation of bLF-CUR activated complex dependent on the temperature.

427

428 Interestingly, the coefficients of polynomial fitting for ΔH_a^\ddagger , and $T\Delta S_a^\ddagger$ vs. T were
 429 very similar between themselves, for association (Eqs. 14 and 15) and dissociation
 430 phase (Eqs. 16 and 17). In addition, the ΔG_a^\ddagger and ΔG_d^\ddagger values maintained almost
 431 constant in this temperature range (Eqs. 18 and 19), indicating the occurrence "iso-
 432 kinetic compensation" discussed above.

433
$$\Delta H_a^\ddagger = 0.24 T^2 - 142.57 T + 20446.23, R^2 = 0.99 \quad (14)$$

434
$$T\Delta S_a^\ddagger = 0.25 T^2 - 145.91 T + 20903.74, R^2 = 0.99 \quad (15)$$

435 $\Delta H_d^\ddagger = 0.67 T^2 - 390.53 T + 56085.93, R^2 = 0.99$ (16)

436 $T\Delta S_d^\ddagger = 0.69 T^2 - 398.88 T + 57270.41, R^2 = 0.99$ (17)


437 $\Delta G_d^\ddagger = 0.14 T + 11.08, R^2 = 0.96$ (18)

438 $\Delta G_d^\ddagger = 0.24 T + 2.19, R^2 = 0.92$ (19)

439

440 To confirm the occurrence "iso-kinetic compensation phenomena in the
 441 association and dissociation phases to bLF-CUR activated complex formation, the
 442 $T\Delta S^\ddagger$ vs. ΔH^\ddagger data were plotted (Figure 8).

443



444

445 Figure 8 – $T\Delta S^\ddagger$ vs. ΔH^\ddagger plot for formation of bLF-CUR activated complex from: (■)
 446 association of free bLF and CUR ($R^2 = 0.99$), and (○) dissociation of thermodynamically
 447 stable bLF-CUR complex ($R^2 = 0.99$).

448

449 The slopes of each fitting were 0.9603 ($R^2 = 0.9993$) and 0.9749 ($R^2 = 0.9995$),
 450 for association and dissociation phases, respectively. In the context of formation of
 451 activated bLF-CUR complex, the EEC is mainly related to the desolvation phenomenon
 452 and to the change of conformation of the bLF-binding site, which cause an increase in
 453 the system enthalpy and in the entropy of the system.

454

455 **4. Conclusions**

456 The experimental results of this study provided thermodynamic and kinetic
457 information on the interactions between bLF and CUR. Fluorescence data showed that
458 fluorescence quenching of bLF was due to the formation of complexes with CUR, with
459 one molecule of CUR bound to each bLF site. The thermodynamic parameters
460 revealed that hydrophobic interactions were predominant in the bLF-CUR complex
461 formation.

462 By SPR, we confirm the occurrence of interaction between CUR and bLF, and
463 verify that the process of association of bLF and CUR molecules and dissociation of
464 bLF-CUR complexes involves conformational changes in the protein. In addition, we
465 have verified that the process of formation of the bLF-CUR complex is governed by a
466 process known as enthalpy-entropy compensation. The kinetic study of the formation of
467 bLF-CUR complex, suggests that at low temperatures the CUR interacts at the bLF
468 interface, and with increasing temperature the CUR penetrates inside the protein.

469 The thermodynamic and kinetic parameters determined in this study are
470 meaningful for a better understanding of the bLF-CUR binding process, further helpful
471 in using this biofunctional complex in food formulations.

472 **Acknowledgments**

473 We are grateful to the Coordenação de Aperfeiçoamento de Pessoal de Nível
474 Superior – Brasil (CAPES) – Finance Code 001, Conselho Nacional de
475 Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à
476 Pesquisa do Estado de Minas Gerais (FAPEMIG).

477 **5. References**

478 (1) Farnaud, S.; Evans, R. W. Lactoferrin - A multifunctional protein with
479 antimicrobial properties. *Mol. Immunol.* **2003**, *40* (7), 395–405.

- 480 (2) Steijns, J. M.; van Hooijdonk, A. C. M. Occurrence, structure, biochemical
481 properties and technological characteristics of lactoferrin. *Br. J. Nutr.* **2000**, *84*
482 (S1).
- 483 (3) Croguennec, T.; Li, N.; Phelebon, L.; Garnier-Lambrouin, F.; Gésan-Guiziou, G.
484 Interaction between lactoferrin and casein micelles in skimmed milk. *Int. Dairy J.*
485 **2012**, *27* (1–2), 34–39.
- 486 (4) Darwish, S.; Mozaffari, S.; Parang, K.; Tiwari, R. Cyclic peptide conjugate of
487 curcumin and doxorubicin as an anticancer agent. *Tetrahedron Lett.* **2017**, *58*
488 (49), 4617–4622.
- 489 (5) Hussain, Z.; Thu, H. E.; Amjad, M. W.; Hussain, F.; Ahmed, T. A.; Khan, S.
490 Exploring recent developments to improve antioxidant, anti-inflammatory and
491 antimicrobial efficacy of curcumin: A review of new trends and future
492 perspectives. *Mater. Sci. Eng. C* **2017**, *77*, 1316–1326.
- 493 (6) Ward, P. P.; Paz, E.; Conneely, O. M. Multifunctional roles of lactoferrin: A
494 critical overview. *Cell. Mol. Life Sci.* **2005**, *62* (22), 2540–2548.
- 495 (7) Sreedhara, A.; Flengsrud, R.; Langsrud, T.; Kaul, P.; Prakash, V.; Vegarud, G.
496 E. Structural characteristic, pH and thermal stabilities of apo and holo forms of
497 caprine and bovine lactoferrins. *BioMetals* **2010**, *23* (6), 1159–1170.
- 498 (8) Ripolles, D.; Harouna, S.; Parrón, J. A.; Calvo, M.; Pérez, M. D.; Carramiñana, J.
499 J.; Sánchez, L. Antibacterial activity of bovine milk lactoferrin and its
500 hydrolysates prepared with pepsin, chymosin and microbial rennet against
501 foodborne pathogen *Listeria monocytogenes*. *Int. Dairy J.* **2015**, *45*, 15–22.
- 502 (9) Iglesias-Figueroa, B. F.; Espinoza-Sánchez, E. A.; Siqueiros-Cendón, T. S.;
503 Rascón-Cruz, Q. Lactoferrin as a nutraceutical protein from milk, an overview.
504 *Int. Dairy J.* **2019**, *89*, 37–41.
- 505 (10) Bokkhim, H.; Bansal, N.; Grøndahl, L.; Bhandari, B. Interactions between
506 different forms of bovine lactoferrin and sodium alginate affect the properties of
507 their mixtures. *Food Hydrocoll.* **2015**, *48*, 38–46.
- 508 (11) Wakabayashi, H.; Yamauchi, K.; Takase, M. Lactoferrin research, technology

- 509 and applications. *Int. Dairy J.* **2006**, *16* (11), 1241–1251.
- 510 (12) TOMITA, M.; WAKABAYASHI, H.; SHIN, K.; YAMAUCHI, K.; YAESHIMA, T.;
511 IWATSUKI, K. Twenty-five years of research on bovine lactoferrin applications.
512 *Biochimie* **2009**, *91* (1), 52–57.
- 513 (13) Yang, W.; Liu, F.; Xu, C.; Yuan, F.; Gao, Y. Molecular interaction between (-)-
514 epigallocatechin-3-gallate and bovine lactoferrin using multi-spectroscopic
515 method and isothermal titration calorimetry. *Food Res. Int.* **2014**, *64*, 141–149.
- 516 (14) Ferraro, V.; Madureira, A. R.; Sarmiento, B.; Gomes, A.; Pintado, M. E. Study of
517 the interactions between rosmarinic acid and bovine milk whey protein α -
518 Lactalbumin, β -Lactoglobulin and Lactoferrin. *Food Res. Int.* **2015**, *77*, 450–459.
- 519 (15) Jain, B. A spectroscopic study on stability of curcumin as a function of pH in
520 silica nanoformulations, liposome and serum protein. *J. Mol. Struct.* **2017**, *1130*,
521 194–198.
- 522 (16) Stankovic, I. Curcumin. *Joint FAO/WHO Expert Committee on Food Additives*.
523 2004, pp 1–8.
- 524 (17) Bharal, N.; Sahaya, K.; Jain, S.; Mediratta, P. K.; Sharma, K. K. Curcumin has
525 anticonvulsant activity on increasing current electroshock seizures in mice.
526 *Phyther. Res.* **2008**, *22* (12), 1660–1664.
- 527 (18) Noratto, G. D.; Jutooru, I.; Safe, S.; Angel-Morales, G.; Mertens-Talcott, S. U.
528 The drug resistance suppression induced by curcuminoids in colon cancer SW-
529 480 cells is mediated by reactive oxygen species-induced disruption of the
530 microRNA-27a-ZBTB10-Sp axis. *Mol. Nutr. Food Res.* **2013**, *57* (9), 1638–1648.
- 531 (19) Ying, M.; Huang, F.; Ye, H.; Xu, H.; Shen, L.; Huan, T.; Huang, S.; Xie, J.; Tian,
532 S.; Hu, Z.; et al. Study on interaction between curcumin and pepsin by
533 spectroscopic and docking methods. *Int. J. Biol. Macromol.* **2015**, *79*, 201–208.
- 534 (20) Shin, G. H.; Li, J.; Cho, J. H.; Kim, J. T.; Park, H. J. Enhancement of Curcumin
535 Solubility by Phase Change from Crystalline to Amorphous in Cur-TPGS
536 Nanosuspension. *J. Food Sci.* **2016**, *81* (2), N494–N501.
- 537 (21) Maiti, K.; Mukherjee, K.; Gantait, A.; Saha, B. P.; Mukherjee, P. K. Curcumin–

- 538 phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic
539 study in rats. *Int. J. Pharm.* **2007**, *330* (1–2), 155–163.
- 540 (22) Wang, X.; Jiang, Y.; Wang, Y.-W.; Huang, M.-T.; Ho, C.-T.; Huang, Q.
541 Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions.
542 *Food Chem.* **2008**, *108* (2), 419–424.
- 543 (23) Ge, Y.-S.; Jin, C.; Song, Z.; Zhang, J.-Q.; Jiang, F.-L.; Liu, Y. Multi-spectroscopic
544 analysis and molecular modeling on the interaction of curcumin and its
545 derivatives with human serum albumin: A comparative study. *Spectrochim. Acta*
546 *Part A Mol. Biomol. Spectrosc.* **2014**, *124*, 265–276.
- 547 (24) Mangolim, C. S.; Moriwaki, C.; Nogueira, A. C.; Sato, F.; Baesso, M. L.; Neto, A.
548 M.; Matioli, G. Curcumin- β -cyclodextrin inclusion complex: Stability, solubility,
549 characterisation by FT-IR, FT-Raman, X-ray diffraction and photoacoustic
550 spectroscopy, and food application. *Food Chem.* **2014**, *153*, 361–370.
- 551 (25) Esmaili, M.; Ghaffari, S. M.; Moosavi-Movahedi, Z.; Atri, M. S.; Sharifzadeh, A.;
552 Farhadi, M.; Yousefi, R.; Chobert, J.-M.; Haertlé, T.; Moosavi-Movahedi, A. A.
553 Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin;
554 food industry application. *LWT - Food Sci. Technol.* **2011**, *44* (10), 2166–2172.
- 555 (26) Hudson, E. A.; de Paula, H. M. C.; Ferreira, G. M. D.; Ferreira, G. M. D.;
556 Hespanhol, M. do C.; da Silva, L. H. M.; Pires, A. C. dos S. Thermodynamic and
557 kinetic analyses of curcumin and bovine serum albumin binding. *Food Chem.*
558 **2018**, *242*, 505–512.
- 559 (27) García-Montoya, I. A.; Cendón, T. S.; Arévalo-Gallegos, S.; Rascón-Cruz, Q.
560 Lactoferrin a multiple bioactive protein: An overview. *Biochim. Biophys. Acta -*
561 *Gen. Subj.* **2012**, *1820* (3), 226–236.
- 562 (28) Sharma, S.; Sinha, M.; Kaushik, S.; Kaur, P.; Singh, T. P. C-lobe of lactoferrin:
563 The whole story of the half-molecule. *Biochem. Res. Int.* **2013**, No. May.
- 564 (29) Bollimpelli, V. S.; Kumar, P.; Kumari, S.; Kondapi, A. K. Neuroprotective effect of
565 curcumin-loaded lactoferrin nano particles against rotenone induced
566 neurotoxicity. *Neurochem. Int.* **2016**, *95*, 37–45.

- 567 (30) Atrahimovich, D.; Vaya, J.; Tavori, H.; Khatib, S. Glabridin Protects Paraoxonase
568 1 from Linoleic Acid Hydroperoxide Inhibition via Specific Interaction: A
569 Fluorescence-Quenching Study. *J. Agric. Food Chem.* **2012**, *60* (14), 3679–
570 3685.
- 571 (31) Schasfoort, R. B. M.; Tudos, A. J. *Handbook of Surface Plasmon Resonance*;
572 2013; Vol. 53.
- 573 (32) Atale, S. S.; Dyawanapelly, S.; Jagtap, D. D.; Jain, R.; Dandekar, P.
574 Understanding the nano-bio interactions using real-time surface plasmon
575 resonance tool. *Int. J. Biol. Macromol.* **2019**, *123*, 97–107.
- 576 (33) Gombau, J.; Nadal, P.; Canela, N.; Gómez-Alonso, S.; García-Romero, E.;
577 Smith, P.; Hermosín-Gutiérrez, I.; Canals, J. M.; Zamora, F. Measurement of the
578 interaction between mucin and oenological tannins by Surface Plasmon
579 Resonance (SPR); relationship with astringency. *Food Chem.* **2019**, *275*, 397–
580 406.
- 581 (34) de Paula, H. M. C.; Coelho, Y. L.; Agudelo, A. J. P.; Rezende, J. de P.; Ferreira,
582 G. M. D.; Ferreira, G. M. D.; Pires, A. C. dos S.; da Silva, L. H. M. Kinetics and
583 thermodynamics of bovine serum albumin interactions with Congo red dye.
584 *Colloids Surfaces B Biointerfaces* **2017**, *159*, 737–742.
- 585 (35) Bi, H.; Tang, L.; Gao, X.; Jia, J.; Lv, H. Spectroscopic analysis on the binding
586 interaction between tetracycline hydrochloride and bovine proteins β -casein, α -
587 lactalbumin. *J. Lumin.* **2016**, *178*, 72–83.
- 588 (36) Lakowicz, J. R. *Principles of fluorescence spectroscopy*; 2006.
- 589 (37) Silva, M. S.; García-Estévez, I.; Brandão, E.; Mateus, N.; de Freitas, V.; Soares,
590 S. Molecular Interaction Between Salivary Proteins and Food Tannins. *J. Agric.*
591 *Food Chem.* **2017**, *65* (31), 6415–6424.
- 592 (38) Lelis, C. A.; Hudson, E. A.; Ferreira, G. M. D.; Ferreira, G. M. D.; da Silva, L. H.
593 M.; da Silva, M. do C. H.; Pinto, M. S.; Pires, A. C. dos S. Binding
594 thermodynamics of synthetic dye Allura Red with bovine serum albumin. *Food*
595 *Chem.* **2017**, *217*, 52–58.

- 596 (39) Nunes, N. M.; Pacheco, A. F. C.; Agudelo, Á. J. P.; da Silva, L. H. M.; Pinto, M.
597 S.; Hespanhol, M. do C.; Pires, A. C. dos S. Interaction of cinnamic acid and
598 methyl cinnamate with bovine serum albumin: A thermodynamic approach. *Food*
599 *Chem.* **2017**, *237*, 525–531.
- 600 (40) Mohammadi, F.; Moeeni, M. Study on the interactions of trans-resveratrol and
601 curcumin with bovine α -lactalbumin by spectroscopic analysis and molecular
602 docking. *Mater. Sci. Eng. C* **2015**, *50*, 358–366.
- 603 (41) Mohammadi, F.; Bordbar, A.-K.; Divsalar, A.; Mohammadi, K.; Saboury, A. A.
604 Interaction of Curcumin and Diacetylcurcumin with the Lipocalin Member β -
605 Lactoglobulin. *Protein J.* **2009**, *28* (3–4), 117–123.
- 606 (42) Bolel, P.; Mahapatra, N.; Halder, M. Optical Spectroscopic Exploration of Binding
607 of Cochineal Red A with Two Homologous Serum Albumins. *J. Agric. Food*
608 *Chem.* **2012**, *60*, 3727–3734.
- 609 (43) Patching, S. G. Surface plasmon resonance spectroscopy for characterisation of
610 membrane protein–ligand interactions and its potential for drug discovery.
611 *Biochim. Biophys. Acta - Biomembr.* **2014**, *1838* (1), 43–55.
- 612 (44) Ferrante, A.; Gorski, J. Enthalpy-entropy compensation and cooperativity as
613 thermodynamic epiphenomena of structural flexibility in ligand-receptor
614 interactions. *J. Mol. Biol.* **2012**, *417* (5), 454–467.
- 615 (45) Bou-Abdallah, F.; Sprague, S. E.; Smith, B. M.; Giffune, T. R. Binding
616 thermodynamics of Diclofenac and Naproxen with human and bovine serum
617 albumins: A calorimetric and spectroscopic study. *J. Chem. Thermodyn.* **2016**,
618 *103*, 299–309.
- 619 (46) Niedzwiecka, A.; Stepinski, J.; Darzynkiewicz, E.; Sonenberg, N.; Stolarski, R.
620 Positive Heat Capacity Change upon Specific Binding of Translation Initiation
621 Factor eIF4E to mRNA 5' Cap Positive Heat Capacity Change upon Specific
622 Binding of Translation Initiation Factor eIF4E to mRNA 5' Cap †. *Biochemistry*
623 **2002**, 12140–12148.
- 624 (47) Perozzo, R.; Folkers, G.; Scapozza, L. Thermodynamics of protein-ligand

- 625 interactions: History, presence, and future aspects. *J. Recept. Signal Transduct.*
626 **2004**, 24 (1–2), 1–52.
- 627 (48) Smith, I. W. M. The temperature-dependence of elementary reaction rates:
628 beyond Arrhenius. *Chem. Soc. Rev.* **2008**, 37 (4), 812–826.
- 629 (49) Pan, A.; Biswas, T.; Rakshit, A. K.; Moulik, S. P. Enthalpy–Entropy
630 Compensation (EEC) Effect: A Revisit. *J. Phys. Chem. B* **2015**, 119 (52), 15876–
631 15884.
- 632 (50) Cheng, L.-Y.; Xia, W.; Zhang, X.; Bai, A.-M.; Ouyang, Y.; Hu, Y.-J. In vitro
633 binding comparison of cephalosporins to human serum albumin by spectroscopy
634 and molecular docking approaches: A novel structural pursuing. *J. Mol. Liq.*
635 **2017**, 248, 168–176.
- 636 (51) KuKanich, B.; Gehring, R.; Webb, A. I.; Craigmill, A. L.; Riviere, J. E. Effect of
637 formulation and route of administration on tissue residues and withdrawal times.
638 *J. Am. Vet. Med. Assoc.* **2005**, 227 (10), 1574–1577.
- 639 (52) Martins, M. T.; Barreto, F.; Hoff, R. B.; Jank, L.; Arsand, J. B.; Motta, T. M. C.;
640 Schapoval, E. E. S. Multiclass and multi-residue determination of antibiotics in
641 bovine milk by liquid chromatography–tandem mass spectrometry: Combining
642 efficiency of milk control and simplicity of routine analysis. *Int. Dairy J.* **2016**, 59,
643 44–51.
- 644 (53) BROWN, S. A. Fluoroquinolones in animal health. *J. Vet. Pharmacol. Ther.*
645 **1996**, 19 (1), 1–14.
- 646 (54) Attili, A. R.; Preziuso, S.; Ngu Ngwa, V.; Cantalamessa, A.; Moriconi, M.; Cuteri,
647 V. Clinical evaluation of the use of enrofloxacin against *Staphylococcus aureus*
648 clinical mastitis in sheep. *Small Rumin. Res.* **2016**, 136, 72–77.
- 649 (55) Giguère, S.; Dowling, P. M. Fluoroquinolones. In *Antimicrobial Therapy in*
650 *Veterinary Medicine*; John Wiley & Sons, Inc: Hoboken, NJ, 2013; pp 295–314.
- 651 (56) Idowu, O. R.; Peggins, J. O.; Cullison, R.; Bredow, J. von. Comparative
652 pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and
653 beef steers following intravenous administration of enrofloxacin. *Res. Vet. Sci.*

- 654 **2010**, *89* (2), 230–235.
- 655 (57) Liu, Z.; Chan, L.; Ye, X.; Bai, Y.; Chen, T. BSA-Based Cu₂Se Nanoparticles
656 with Multistimuli-Responsive Drug Vehicles for Synergistic Chemo-Photothermal
657 Therapy. *Colloids Surfaces B Biointerfaces* **2018**.
- 658 (58) Salehiabar, M.; Nosrati, H.; Javani, E.; Aliakbarzadeh, F.; Kheiri Manjili, H.;
659 Davaran, S.; Danafar, H. Production of biological nanoparticles from bovine
660 serum albumin as controlled release carrier for curcumin delivery. *Int. J. Biol.*
661 *Macromol.* **2018**, *115*, 83–89.
- 662 (59) McCann, D.; Barrett, A.; Cooper, A.; Crumpler, D.; Dalen, L.; Grimshaw, K.;
663 Kitchin, E.; Lok, K.; Porteous, L.; Prince, E.; et al. Food additives and
664 hyperactive behaviour in 3-year-old and 8/9-year-old children in the community:
665 a randomised, double-blinded, placebo-controlled trial. *Lancet* **2007**, *370* (9598),
666 1560–1567.
- 667 (60) Lin, Y.; Jiao, G.; Sun, G.; Zhang, L.; Wang, S.; Liu, H.; Li, Z. Binding of
668 teicoplanin and vancomycin to bovine serum albumin in vitro: A
669 multispectroscopic approach and molecular modeling. *Luminescence* **2014**, *29*
670 (2), 109–117.
- 671 (61) Jattinagoudar, L.; Meti, M.; Nandibewoor, S.; Chimatadar, S. Evaluation of the
672 binding interaction between bovine serum albumin and dimethyl fumarate, an
673 anti-inflammatory drug by multispectroscopic methods. *Spectrochim. Acta - Part*
674 *A Mol. Biomol. Spectrosc.* **2016**, *156*, 164–171.
- 675 (62) Guo, M.; Lu, W.-J.; Yi, P.-G.; Yu, Q.-S. Study on the thermodynamic
676 characteristics between fluoroquinolone and bovine serum albumin. *J. Chem.*
677 *Thermodyn.* **2007**, *39* (3), 337–343.
- 678 (63) Seedher, N.; Agarwal, P. Complexation of fluoroquinolone antibiotics with human
679 serum albumin: A fluorescence quenching study. *J. Lumin.* **2010**, *130* (10),
680 1841–1848.
- 681 (64) Liu, B.; Xue, C.; Wang, J.; Yang, C.; Lv, Y. Study of the quenching mechanism
682 of bovine serum albumin with presence of chloramphenicol and enrofloxacin.

- 683 *Phys. Chem.* **2011**, 6 (2).
- 684 (65) Ni, Y.; Su, S.; Kokot, S. Spectrometric studies on the interaction of
685 fluoroquinolones and bovine serum albumin. *Spectrochim. Acta - Part A Mol.*
686 *Biomol. Spectrosc.* **2010**, 75 (2), 547–552.
- 687 (66) Reddy, T. K.; Srikanth, G.; Mallikarjun, V.; Nivethithai, P. MECHANISM OF
688 INTERACTION OF SOME ANTIMICROBIAL AGENTS WITH BOVINE SERUM
689 ALBUMIN. *J. Glob. Pharma Technol.* **2009**, 2 (March 2010), 47–55.
- 690 (67) Qin, P.; Pan, X.; Liu, R.; Hu, C.; Dong, Y. Toxic interaction mechanism of two
691 fluoroquinolones with serum albumin by spectroscopic and computational
692 methods. *J. Environ. Sci. Heal. - Part B Pestic. Food Contam. Agric. Wastes*
693 **2017**, 52 (11), 833–841.
- 694 (68) Wang, L.; Zhang, G.; Wang, Y. Binding properties of food colorant allura red with
695 human serum albumin in vitro. *Mol. Biol. Rep.* **2014**, 41 (5), 3381–3391.
- 696 (69) Ma, L.; Liu, B.; Wang, C.; Zhang, H.; Cheng, X. The Investigation of
697 Fluorescence Spectra and Fluorescence Quantum Yield of Enrofloxacin. **2018**, 2
698 (1), 11–16.
- 699 (70) Lizondo, M.; Pons, M.; Gallardo, M.; Estelrich, J. Physicochemical properties of
700 enrofloxacin. *J. Pharm. Biomed. Anal.* **1997**, 15 (12), 1845–1849.
- 701 (71) Bi, S.; Song, D.; Tian, Y.; Zhou, X.; Liu, Z.; Zhang, H. Molecular spectroscopic
702 study on the interaction of tetracyclines with serum albumins. *Spectrochim. Acta*
703 *- Part A Mol. Biomol. Spectrosc.* **2005**, 61 (4), 629–636.
- 704 (72) Schneider, M. J. Rapid Fluorescence Screening Assay for Enrofloxacin and
705 Tetracyclines in Chicken Muscle. *J. Agric. Food Chem.* **2004**, 52 (26), 7809–
706 7813.
- 707 (73) Yazdi, S. R.; Corredig, M. Heating of milk alters the binding of curcumin to
708 casein micelles . A fluorescence spectroscopy study. *Food Chem.* **2012**, 132 (3),
709 1143–1149.
- 710 (74) Benesi, H. A.; Hildebrand, J. H. a Spectrophotometric Investigation of the
711 Interaction of Iodine With Aromatic Hydrocarbons. *J. Am. Chem. Soc.* **1949**, 71

- 712 (8), 2703–2707.
- 713 (75) Bensouilah, N.; Abdaoui, M. Inclusion complex of N-nitroso, N-(2-chloroethyl),
714 N', N'-dibenzylsulfamid with β -Cyclodextrin: Fluorescence and molecular
715 modeling. *Comptes Rendus Chim.* **2012**, *15* (11–12), 1022–1036.
- 716 (76) Otagiri, M. A Molecular Functional Study on the Interactions of Drugs with
717 Plasma Proteins. *Drug Metab. Pharmacokinet.* **2005**, *20* (5), 309–323.
- 718 (77) Roy, S. Review on Interaction of Serum Albumin with Drug Molecules. *Res. Rev.*
719 *J. Pharmacol. Toxicol. Stud.* **2016**, *4* (2), 1–10.
- 720 (78) Ming Guo, Wei-Jun Lu, Ping-Gui Yi, Q.-S. Y. Study on the thermodynamic
721 characteristics between fluoroquinolone and bovine serum albumin. *J. Chem.*
722 *Thermodyn.* **2007**, *39*, 337–343.
- 723 (79) Sinisi, V.; Forzato, C.; Cefarin, N.; Navarini, L.; Berti, F. Interaction of
724 chlorogenic acids and quinides from coffee with human serum albumin. *FOOD*
725 *Chem.* **2015**, *168*, 332–340.
- 726 (80) Bourassa, P.; Kanakis, C. D.; Tarantilis, P.; Pollissiou, M. G.; Tajmir-Riahi, H. a.
727 Resveratrol, genistein, and curcumin bind bovine serum albumin. *J. Phys.*
728 *Chem. B* **2010**, *114* (9), 3348–3354.
- 729 (81) Pal, U.; Pramanik, S. K.; Bhattacharya, B.; Banerji, B.; Maiti, N. C. Binding
730 interaction of a novel fluorophore with serum albumins: steady state
731 fluorescence perturbation and molecular modeling analysis. *Springerplus* **2015**,
732 *4* (1).
- 733 (82) Li, M.; Hagerman, A. E. Role of the Flavan-3-ol and Galloyl Moieties in the
734 Interaction of (-)-Epigallocatechin Gallate with Serum Albumin. *J. Agric. Food*
735 *Chem.* **2014**, *62* (17), 3768–3775.
- 736 (83) Datta, S.; Mahapatra, N.; Halder, M. pH-insensitive electrostatic interaction of
737 carmoisine with two serum proteins: A possible caution on its uses in food and
738 pharmaceutical industry. *J. Photochem. Photobiol. B Biol.* **2013**, *124*, 50–62.
- 739 (84) Majorek, K. A.; Porebski, P. J.; Dayal, A.; Zimmerman, M. D.; Jablonska, K.;
740 Stewart, A. J.; Chruszcz, M.; Minor, W. Structural and immunologic

- 741 characterization of bovine, horse, and rabbit serum albumins. *Mol. Immunol.*
742 **2012**, 52 (3–4), 174–182.
- 743 (85) Khatun, S.; Riyazuddeen; Yasmeen, S.; Kumar, A.; Subbarao, N. Calorimetric,
744 spectroscopic and molecular modelling insight into the interaction of gallic acid
745 with bovine serum albumin. *J. Chem. Thermodyn.* **2018**, 122, 85–94.
- 746 (86) Kaur, A.; Khan, I. A.; Banipal, P. K.; Banipal, T. S. Deciphering the complexation
747 process of a fluoroquinolone antibiotic, levofloxacin, with bovine serum albumin
748 in the presence of additives. *Spectrochim. Acta - Part A Mol. Biomol. Spectrosc.*
749 **2018**, 191, 259–270.
- 750 (87) Yuan, J.-L.; Lv, Z.; Liu, Z.-G.; Hu, Z.; Zou, G.-L. Study on interaction between
751 apigenin and human serum albumin by spectroscopy and molecular modeling. *J.*
752 *Photochem. Photobiol. A Chem.* **2007**, 191 (2–3), 104–113.
- 753 (88) Ross, P. D.; Subramanian, S. Thermodynamics of protein association reactions:
754 forces contributing to stability. *Biochemistry* **1981**, 20 (11), 3096–3102.
- 755 (89) Cui, F.-L.; Wang, J.-L.; Cui, Y.-R.; Li, J.-P. Fluorescent investigation of the
756 interactions between N-(p-chlorophenyl)-N'-(1-naphthyl) thiourea and serum
757 albumin: Synchronous fluorescence determination of serum albumin. *Anal.*
758 *Chim. Acta* **2006**, 571 (2), 175–183.
- 759 (90) Basu, A.; Kumar, G. S. Thermodynamics of the interaction of the food additive
760 tartrazine with serum albumins: a microcalorimetric investigation. *Food Chem.*
761 **2015**, 175, 137–142.
- 762 (91) Bou-Abdallah, F.; Sprague, S. E.; Smith, B. M.; Giffune, T. R. Binding
763 thermodynamics of Diclofenac and Naproxen with human and bovine serum
764 albumins: A calorimetric and spectroscopic study. *J. Chem. Thermodyn.* **2016**,
765 103, 299–309.
- 766 (92) Chaires, J. B. Calorimetry and Thermodynamics in Drug Design. *Annu. Rev.*
767 *Biophys.* **2008**, 37 (1), 135–151.
- 768 (93) Chodera, J. D.; Mobley, D. L. Entropy-enthalpy compensation: Role and
769 ramifications in biomolecular ligand recognition and design. *Annu Rev Biophys*

- 770 **2014**, 42, 121–142.
- 771 (94) Sturtevant, J. M. Heat capacity and entropy changes in processes involving
772 proteins. *Proc. Natl. Acad. Sci.* **1977**, 74 (6), 2236–2240.
- 773 (95) Perozzo, R.; Folkers, G.; Scapozza, L. Thermodynamics of protein-ligand
774 interactions: history, presence, and future aspects. *J. Recept. Signal Transduct.*
775 *Res.* **2004**, 24 (1–2), 1–52.
- 776 (96) Saini, R. D. Thermodynamics of protein-ligand interactions and their analysis. *J.*
777 *Proteins Proteomics* **2017**, 8 (4), 205–217.
- 778 (97) Ford, D. M. Enthalpy–Entropy Compensation is Not a General Feature of Weak
779 Association. *J. Am. Chem. Soc.* **2005**, 127 (46), 16167–16170.
- 780 (98) Ball, V.; Maechling, C. Isothermal microcalorimetry to investigate non specific
781 interactions in biophysical chemistry. *Int. J. Mol. Sci.* **2009**, 10 (8), 3283–3315.
- 782 (99) Molina-Bolívar, J. A.; Ruiz, C. C.; Galisteo-González, F.; O'Donnell, M. M.;
783 Parra, A. Energetics of albumin-disuccinylmaslinic acid binding determined by
784 fluorescence spectroscopy. *Fluid Phase Equilib.* **2015**, 400, 43–52.
- 785 (100) Banerjee, T.; Singh, S. K.; Kishore, N. Binding of Naproxen and Amitriptyline to
786 Bovine Serum Albumin: Biophysical Aspects. *J. Phys. Chem. B* **2006**, 110 (47),
787 24147–24156.
- 788 (101) Xu, Y.; Oruganti, S. V.; Gopalan, V.; Foster, M. P. Thermodynamics of coupled
789 folding in the interaction of archaeal RNase P proteins RPP21 and RPP29.
790 *Biochemistry* **2012**, 51 (4), 926–935.
- 791 (102) Spolar, R.; Record, M. Coupling of local folding to site-specific binding of
792 proteins to DNA. *Science (80-.)*. **1994**, 263 (5148), 777–784.
- 793 (103) Banipal, T. S.; Kaur, N.; Banipal, P. K. Binding studies of caffeine and
794 theophylline to bovine serum albumin: Calorimetric and spectroscopic approach.
795 *J. Mol. Liq.* **2016**, 223, 1048–1055.
- 796 (104) Vega, S.; Abian, O.; Velazquez-Campoy, A. On the link between conformational
797 changes, ligand binding and heat capacity. *Biochim. Biophys. Acta - Gen. Subj.*
798 **2016**, 1860 (5), 868–878.

799 **Capítulo 2: Interactions of enrofloxacin with bovine serum albumin: A detailed**
800 **thermodynamic study by fluorescence spectroscopy**
801

802 **Abstract**

803 A more comprehensive study of the thermodynamic parameters of BSA-ENRO
804 complex formation is described in this paper, using fluorescence spectroscopy. Our
805 study suggested that ENRO binds to subdomain IIA (site I) of BSA, interacting with the
806 hydrophobic side chains and positively charged regions. The fluorescence
807 spectroscopy results showed negative values of standard enthalpy and entropy
808 changes ($\Delta H^\circ = -74.07$ to -36.54 $\text{kJ}\cdot\text{mol}^{-1}$ and $T\Delta S^\circ = -45.88$ to -11.12 $\text{kJ}\cdot\text{mol}^{-1}\cdot\text{K}^{-1}$),
809 indicating that the process of forming the BSA-ENRO complex is exothermic. The
810 Gibbs free energy change standard values were negative ($\Delta G^\circ = -28.19$ to -25.42
811 $\text{kJ}\cdot\text{mol}^{-1}$), however, it showed a small variation as a function of temperature. This
812 behavior may be due to the occurrence of the enthalpy-entropy compensation (EEC),
813 which was confirmed by the linearity of the $T\Delta S^\circ$ and ΔG° vs ΔH° graph. It was also
814 obtained in the study the standard heat capacity change, ΔC_p° , which presented a
815 value of 1.24 $\text{kJ}\cdot\text{K}^{-1}\cdot\text{mol}^{-1}$, thus showing that the complex formed between BSA and
816 ENRO has a greater ability to transfer energy to the potential form than the free
817 molecules. Thus, in this study we obtained a more detailed study of the interaction
818 between BSA and ENRO, which is of great importance for future application studies.

819

820 **Keywords:** enrofloxacin, bovine serum albumin, fluorescence spectroscopy

821

822

823 **1. Introduction**

824 The use of antibiotics in the treatment of bacterial infections has triggered global
825 attention from the point of view of food safety⁵⁰⁻⁵². The main features of antimicrobial

826 agent are its high bioavailability, low toxicity to the host, and excellent penetration into
827 the fabric^{53,54}. However, drug residues can be found in food like milk when good
828 veterinary practices are not performed.

829 Enrofloxacin (ENRO) was the first synthetic fluoroquinolone introduced and
830 approved as an antibacterial agent developed for veterinary application, highly effective
831 against a broad spectrum of Gram-positive and Gram-negative bacteria⁵⁵. It is
832 registered in several countries including the US and Europe, with potential for the
833 treatment of infections in cow⁵⁶.

834 The study on the effect/influence of drugs on the protein constituents of the
835 circulatory system is of great interest, since the interaction of the drugs with the
836 transport proteins can affect both the availability of the drug and the functioning of the
837 proteins. One of the functions of transport proteins is their effective role in the delivery
838 of drugs and other substances^{57,58}, thus playing an important in biological processes.

839 The serum albumins have been used for initial studies with drug. The binding
840 capacity of a drug with serum albumin is important to efficacy as an agent
841 pharmaceutical, since the serum albumins are the major proteins responsible for drug
842 delivery in their target organs.

843 Bovine serum albumin (BSA) is the major protein in cow blood plasma and
844 plays important physiological role in the transport of hydrophobic compounds⁵⁹. Also, it
845 is present in milk, arranged in a helical protein conformation heart-shaped consisting of
846 three homologous sites (I, II, III), each domain consists of two separate sites^{60,61}. Many
847 studies of interaction between proteins and drugs use BSA because of their low cost,
848 availability, binding ability and its identity homology (~76%) to human serum albumin
849 (HSA). Thus, BSA can be used as a model protein for the study of protein-drug
850 interaction, providing valuable information.

851 Despite the several reports in the literature on the interaction of ENRO with
852 transport proteins, BSA and HSA⁶²⁻⁶⁷, a comprehensive understanding of the
853 thermodynamic parameters of formation of the BSA-ENRO complex should still be fully

854 understood. For this purpose, all thermodynamic parameters of interaction (ΔG° , ΔS° ,
855 ΔH° and ΔC_p°) as well as their detailed contributions were analyzed in this work. In
856 addition, all the studies reported so far on the interaction between BSA and ENRO are
857 based on changes in protein properties, such as the reduction of their intrinsic
858 fluorescence. In our study, ENRO's ability to emit fluorescence will be used to
859 determine the thermodynamic parameters of the BSA-ENRO interaction.

860 Thus the work aims at a more detailed study of the interaction between BSA
861 and ENRO using fluorescence spectroscopy.

862 **2. Material and Methods**

863 **2.1. Material**

864 BSA (>99% wt.), ENRO (>98% wt.), warfarin (analytical standard), ibuprofen
865 (>98% wt.), digitoxin (>92% wt.) and sodium phosphate (reagent grade) were
866 purchased from Sigma-Aldrich (St. Louis, MO, USA).

867

868 **2.2. Fluorescence experiments**

869 **2.2.1. BSA-ENRO binding**

870 Fluorescence spectra were obtained with a LS55 Fluorescence (Perkin Elmer)
871 spectrofluorimeter equipped with a thermostat bath, according to the procedure of
872 Wang et al. with some modifications⁶⁸. Initially a solution of ENRO $1.0 \times 10^{-3} \text{ mol}\cdot\text{L}^{-1}$ in
873 DMSO was prepared. From this solution was prepared the stock solution of ENRO 1.5
874 $\times 10^{-5} \text{ mol}\cdot\text{L}^{-1}$, in solution of BSA $3.0 \times 10^{-7} \text{ mol}\cdot\text{L}^{-1}$. For fluorescence measurements, 10
875 titrations of 40 μL of a stock solution of ENRO ($3 \times 10^{-7} \text{ mol}\cdot\text{L}^{-1}$ to $3 \times 10^{-6} \text{ mol}\cdot\text{L}^{-1}$) in 2.0
876 mL of BSA solution ($3.0 \times 10^{-7} \text{ mol}\cdot\text{L}^{-1}$) in a quartz cell and at pH 7.4 were used. To
877 minimize the effect of 10 titrations of ENRO containing DMSO on the protein, we added
878 1.5% DMSO to the BSA solution in a quartz cell. Fluorescence emission spectra were
879 then measured at five different temperatures (293.15, 298.15, 308.15 and 323.15 K) in
880 the range 315–600 nm (excitation wavelength, 315 nm).

881 2.2.2. Competitive binding studies

882 The competitive binding studies were carried out using site probes for sites I, II
883 and III of BSA (warfarin, ibuprofen and digitoxin, respectively). For this, BSA and site
884 probes were at fixed concentration ($3.00 \times 10^{-7} \text{ mol.L}^{-1}$) and the fluorescence
885 quenching titration (with ENRO) was performed as described before at pH 7.4. Thus,
886 binding parameters for ENRO-BSA binding were determined in the presence of site
887 markers.


888

889 3. Results and Discussion

890 3.1. Binding of ENRO on BSA studied by fluorescence spectroscopy

891 The ENRO molecule contains in its structure a carboxyl group and a piperazinyl
892 amine group whose fluorescence emission is related to the degree of protonation and
893 is therefore pH dependent⁶⁹. ENRO can emit fluorescence at pH around 7.0 when
894 excited at 275 and 315 nm⁷⁰. However, the wavelength 275 nm is very close to the
895 wavelength of excitation BSA⁷¹, thus we choose to excite ENRO at 315 nm⁷²,
896 wavelength in which the protein did not absorb radiation (Figure 1 (A)).

897 The fluorescence emission spectra of ENRO showed a strong fluorescence
898 emission peak at 415 nm, which enhanced with increasing ENRO concentration in the
899 system (Figure 1 (A)).



900

901 Figure 1: (A) - Fluorescence spectra of increasing ENRO concentration at
902 308.15 K and pH 7.4 ($\lambda_{\text{ex}} = 315 \text{ nm}$ and $\lambda_{\text{em}} = 415 \text{ nm}$) in the presence of BSA (3.0×10^{-7}
903 mol.L^{-1}). Arrow indicates an increase in the ENRO concentration (from 0 to 3.0×10^{-6}
904 mol.L^{-1}). (B) - The double reciprocal plot was obtained on the basis of (1), allowing

905 calculation of the inclusion constant value of the complexes of ENRO and the studied
906 BSA.

907

908 The relationship between the inverse of fluorescence emitted by ENRO vs the
909 inverse of its concentration, through the Benesi-Hildebrand model (Equation 1), yields
910 the binding constant (K_b) for the ENRO–BSA complex formation^{73,74}.

$$911 \quad \frac{1}{\Delta F} = \frac{1}{\Delta F_{\text{máx}}} + \frac{1}{(K_b \Delta F_{\text{máx}} [\text{ENRO}])} \quad (1)$$

912

913 where ΔF is the difference in fluorescence intensity between the sample, with and
914 without enrofloxacin, $\Delta F_{\text{máx}}$ is the value of maximum ΔF at plateau, K_b is the binding
915 constant, and $[\text{ENRO}]$ is the concentration of enrofloxacin (mol.L^{-1}).

916 A linearity ($r = 0.99$) of the curve in the plot $1/\Delta F$ vs. $1/[\text{ENRO}]$ indicated that the
917 complex formation stoichiometry was 1:1, (Figure 1 (B))⁷⁵, i.e., for each ENRO
918 molecule there is one BSA molecule.

919 The affinity of albumin for a particular drug is important to guide the transport of
920 the drug in blood circulation and its release to the target site^{76,77}. The K_b values (Table
921 1) ranged from 1.06×10^5 to $1.29 \times 10^4 \text{ L.mol}^{-1}$ for the temperatures studied at pH 7.4.
922 The K_b decreased with the temperature increase indicating that the complex is more
923 stable at lower temperatures; and considering that $K_b = [\text{BSA} - \text{ENRO}]/[\text{BSA}][\text{ENRO}]$,
924 more complexes were formed at lower than at higher temperatures. The values of the
925 K_b found by Qin et al., 2017 were of the order of 10^3 L.mol^{-1} , about 10 times lower than
926 the value found in our study. The authors also observed variation in K_b values with
927 temperature. At 293 K the value of K_b was $9.0 \times 10^3 \text{ L.mol}^{-1}$, while at 320 K the value of
928 K_b was $5.7 \times 10^3 \text{ L.mol}^{-1}$, this variation of k_b is 5 times smaller than the variation found
929 in our study. This difference in the variation of K_b values can be justified by the use of
930 the fluorescence emission property of different molecules (BSA and ENRO). In our
931 study was used the fluorescence emission capability of ENRO, already in the study of
932 Qin et al., 2017 they used the fluorescence emission property of BSA when excited at
933 280nm⁶⁷. The K_b values found in our study are in agreement with values found in other

934 interaction studies between BSA and ENRO, with K_b values in the order of 10^{-4} L.mol⁻¹
935 ^{78, 66,64}.

936

937 Table 1 – The binding constant (K_b), standard enthalpy change (ΔH°), standard Gibbs
938 free energy change (ΔG°) and standard entropy change ($T\Delta S^\circ$) associated to formation
939 of ENRO-BSA complex at pH = 7.4.

Temperature (K)	K_b (10^4 M ⁻¹)	ΔG° (KJ.mol ⁻¹)	ΔH° (KJ.mol ⁻¹)	$T\Delta S^\circ$ (kJ.mol ⁻¹)
293.15	10.6 ± 0.06	-28.19	-74.07	-45.88
298.15	6.76 ± 0.35	-27.55	-67.29	-39.74
308.15	2.94 ± 0.16	-26.35	-54.39	-28.04
323.15	1.29 ± 0,08	-25.42	-36.54	-11.12

940

941 To identify the ENRO binding site on BSA, we performed competitive binding
942 experiments with three specific site probes. The use of probes that bind to specific sites
943 on protein allows a simple and rapid screening about the link of local drug by
944 macromolecule. BSA is made up of three homologous sites that are linearly arranged,
945 structurally distinct, and evolutionarily related domains (I–III) ^{79,80}, and are involved in
946 transport of different molecules, such as drugs. The binding between BSA and drugs
947 and/or any competitive molecule, such as other medicines, may determine the
948 pharmacological effect of the drug⁸¹. It is known that warfarin binding specifically on
949 site I of BSA, while ibuprofen and digitoxin are markers for BSA sites II and III,
950 respectively ^{82,83}.

951 In the presence of warfarin the K_b value was reduced by 68.64% ($2.12 \pm 0.12 \times$
952 10^4 L.mol⁻¹) compared to ENRO-BSA without any marker ($6.76 \pm 0.41 \times 10^4$ L.mol⁻¹),
953 while in the presence of ibuprofen and digitoxin it had a pronounced increase ($K_b =$
954 $1.80 \pm 0.09 \times 10^5$ L.mol⁻¹ and $K_b = 8.87 \pm 0.09 \times 10^4$ L.mol⁻¹, respectively) . These
955 results indicate that ENRO competes with warfarin for the same binding site in BSA,
956 the subdomain II A, located inside site I. BSA exhibits about 76% sequence homology

957 and identity of tertiary structures to human serum albumin (HSA), which causes both
958 molecules to have homologous binding sites^{84,85}. In a study by Seedher and Agarwal,
959 (2010) they found that ENRO competes with phenylbutazone for the same binding site
960 (site I) as HSA, corroborating with our finding that ENRO binds preferentially to site I.
961 Kaur et al., (2018) studied the interaction between BSA and levofloxacin, a drug with a
962 chemical structure similar to ENRO. In the study the researchers found by molecular
963 docking that levofloxacin binds preferentially to the site I of the BSA. These authors
964 have verified the occurrence of hydrogen bonds, hydrophobic interactions, and other
965 types of interactions like π -cation, charge-charge, and salt bridge between amino acids
966 present in site I of BSA and regions (piperidone carbonyl, carboxylate, piperazine ring)
967 present in the structure of levofloxacin, also present in the structure of ENRO. Qin et al.
968 (2017) had suggested that ENRO binds to subdomain III A (site II) of the BSA. The
969 internal cavity of subdomain IIA (site I) of BSA is formed by hydrophobic side chains,
970 while the entrance of the pocket is surrounded by positively charged residues⁸⁷. ENRO
971 has in its structure hydrophobic group with the benzene ring and ionizable groups (-
972 COOH and -NH) which may interact with the hydrophobic side chains and the charged
973 residues of subdomain IIA of the protein, respectively. In addition, in the work of Qin et
974 al. (2017), they used different markers in relation to those used in our study, which may
975 justify the difference found in relation to the main interaction site of BSA for the ENRO
976 molecule.

977

978 **3.2. Thermodynamic parameters for ENRO–BSA binding**

979 During the formation of complexes between proteins and ligands four main non-
980 covalent bindings may occur, such as hydrogen bonding, van der Waals forces,
981 electrostatic, and hydrophobic bindings. The determination of the thermodynamic
982 binding parameters can help to elucidate the main forces involved in the process of
983 complex formation between BSA and ENRO^{88,89}.

984 To elucidate the main forces of binding between BSA and ENRO,
 985 thermodynamic parameters, such as standard Gibbs free energy change (ΔG°),
 986 standard enthalpy change (ΔH°), standard entropy change (ΔS°), and standard heat
 987 capacity change (ΔC_p°) for complex formation were determined.

988 The ΔG° values were directly calculated from K_b values at each temperature
 989 (Equation 2), the ΔH° values were determined by the non-linear van't Hoff approach
 990 (Equations 3 and 4, Figure 2), and the entropic term ($T\Delta S^\circ$) were obtained using the
 991 fundamental Gibbs equation (Equation 5). The results are shown in Table 1.

$$992 \quad \Delta G^\circ = -RT \ln K_b \quad (2)$$

$$993 \quad \ln K = a + b \left(\frac{1}{T}\right) + c \left(\frac{1}{T}\right)^2 + d \left(\frac{1}{T}\right)^3 + \dots + \ln \Phi \quad (3)$$


$$994 \quad \Delta H^\circ = -R \left[b + 2c \left(\frac{1}{T}\right) + 3d \left(\frac{1}{T}\right)^2 + \dots \right] \quad (4)$$

$$995 \quad T\Delta S^\circ = \Delta H^\circ - \Delta G^\circ \quad (5)$$

996

997 where R is the universal gas constant ($8.3145 \text{ J}\cdot\text{mol}^{-1}\cdot\text{K}^{-1}$), T is the temperature (in K),

998 K_b is the binding constant ($\text{L}\cdot\text{mol}^{-1}$).



999

1000 Figure 2: Non-linear van't Hoff plot for binding of BSA ($3.00 \times 10^{-7} \text{ mol}\cdot\text{L}^{-1}$) and ENRO
 1001 at different temperatures (pH = 7.4).

1002

1003 The non-linear regression of the van't Hoff plot (Figure 2) is common when the

1004 energy sources during the binding come from non-covalent binding⁴⁴.

1005 As shown in Table 1 the ΔH° and $T\Delta S^\circ$ values were negative, being therefore
1006 the formation of the complex driven by the enthalpic term. Thus, the process of
1007 formation of the BSA-ENRO complex were exothermic.

1008 The negative values of ΔH° found for the BSA-ENRO interaction are resultants
1009 of the contribution of three different processes demonstrated in the Equation 6.

$$1010 \quad \Delta H^0 = \Delta H_{des} + \Delta H_{mud.conf} + \Delta H_{BSA-ENRO} \quad (6)$$

1011 Where, ΔH_{des} refers to desolvation of the bLF and CUR surfaces; $\Delta H_{mud.conf}$ is the
1012 conformational change of the bLF interaction site, and $\Delta H_{BSA-ENRO}$ is the formation of
1013 the BSA-ENRO interactions.

1014 Considering that the values of ΔH° were negative, it can be concluded that the
1015 contribution of the exothermic terms $\Delta H_{BSA-ENRO}$ was greater than the contribution of
1016 the endothermic terms ΔH_{des} and $\Delta H_{mud.conf}$.


1017 In a similar way that was discussed for ΔH° , the entropic term (ΔS°) can be
1018 basically dismembered as shown in equation 7.

$$1019 \quad \Delta S^\circ = \Delta S_{conf} + \Delta S_{solv} + \Delta S_{mud.conf} \quad (7)$$

1020 Where, ΔS_{conf} is the configurational entropy change that reflects the reduction of
1021 degrees of freedom when the complex is formed from two free molecules in solution;
1022 ΔS_{solv} describes the entropy change resulting from the release of water molecules from
1023 the solvation shell of ENRO and BSA to form the BSA-ENRO complex; and $\Delta S_{mud.conf}$
1024 refers to conformational changes in the protein interaction site.

1025 During the formation of the BSA-ENRO complex, processes of conformational
1026 adjustments at the binding site of the protein may occur as ligand interacts. This
1027 process is also accompanied by the release of water molecules that are solvating the
1028 ligand and the binding site in the protein. The negative values of ΔS° show that the
1029 processes of conformational adjustments at the binding site of the proteins are more
1030 significant than the release of water molecules from the solvation layer. With increasing
1031 temperature the values of ΔS° became less negative, ie, the contribution of water
1032 release from the solvation layer increases with increasing temperature.

1033 The negative values of ΔG° indicated that, in the temperature range used in our
 1034 study, the BSA-ENRO complex was more stable than the free ENRO and BSA
 1035 molecules in the equilibrium $\text{ENRO} + \text{BSA} \rightleftharpoons \text{BSA-ENRO}$. However, despite the
 1036 remarkable variation of ΔH° and $T\Delta S^\circ$ over the temperature the ΔG° values showed a
 1037 weak variation. Many different thermodynamic processes, such as the interaction
 1038 between BSA, HSA and tartrazine⁹⁰; BSA, HSA and drugs⁹¹; BSA and levofloxacin⁸⁶,
 1039 have shown this kind of behavior, known as enthalpy-entropy compensation (EEC).
 1040 The EEC phenomenon found here (Figure 3) can be described by a reduction on the
 1041 enthalpy accomplished by a reduction in the entropy.
 1042



1043
 1044 Figure 3: Plots of enthalpy-entropy compensation, (○) $T\Delta S^\circ$ vs. ΔH° and (■) ΔG° vs.
 1045 ΔH° for the binding of ENRO to BSA at pH 7.40.


1046
 1047 The enthalpy component reflects the amount of thermal energy change
 1048 associated with binding, while the entropic component quantifies the energy distribution
 1049 changes between the various quantum levels of the ligand (ENRO), protein (BSA) and
 1050 the solvent^{92,93}. The process of binding in aqueous solution is composed of a series of
 1051 processes, including the approximation of the ligand in the protein, the desolvation of
 1052 the ligand and the binding site of the protein, the conformational change of the protein

1053 when the ligand enters its cavity and the solvation of the formed complex. The
1054 desolvation process can result in an increase in the entropy of the system as the
1055 degree of freedom of the water molecules increases^{94,95,96}. However, the binding of the
1056 ligand with the protein may result in a decrease in the entropy of both molecules. The
1057 enthalpy change may be due to formation and breaking of hydrogen and van der Waals
1058 bonds, inducing less or more enthalpy change⁹⁶.

1059 These modifications of the thermodynamic parameters may indicate the
1060 enthalpy-entropy compensation phenomenon, and can be described as following
1061 equation $T\Delta S^\circ = \alpha \Delta H^\circ + \beta$. In fact, as shown in figure 3, a linear relationship was
1062 obtained according to where the slope and the intercept (α and β) were 0.92 and 22.57,
1063 respectively. The slope near of unity suggests that ΔH° are often compensated by
1064 corresponding $T\Delta S^\circ$ ^{97,98,93} that is, the release of energy in the system due to the new
1065 interactions formed during the formation of the complex bLF-CUR is compensated by
1066 the reduction of the entropy of the system due to the conformational changes in the
1067 interaction site. This effect of the enthalpy-entropy compensation for non-covalent
1068 bindings can be confirmed by the linearity of the graph of ΔG° versus ΔH° ^{98,91},
1069 indicating almost complete enthalpy-entropy compensation. Thus despite the observed
1070 change in ΔH° and ΔS° , Gibbs free energy change remained almost unchanged. The
1071 ΔG° values show a narrow range of variation, referring to biological processes involving
1072 any non-chemical reversible type of binding⁹⁹.

1073 From the dependence of ΔH° values on temperature was possible to determine
1074 the standard heat capacity change, ΔC_p° , using the relation: $\Delta C_p^\circ = \left(\frac{\partial H^\circ}{\partial T}\right)_p$.

1075 In Figure 4 it is illustrate the temperature dependence of ΔH° associated with
1076 the binding of ENRO to BSA. A linear fit ($R^2=0.998$) was obtained, and the slope is the
1077 measurement of the heat capacity change between the initial and final states of the
1078 system. The ΔC_p° value was 1.24 kJ K⁻¹ mol⁻¹.



1079

1080 Figure 4: Plot of variation of the standard molar enthalpy change (ΔH°) versus
 1081 temperature for the BSA-ENRO binding.

1082

1083 The ΔC_p° value is an important thermodynamic parameter that provide useful
 1084 information about the type and magnitude of the forces governing the binding as well
 1085 as structural changes of the protein in response to the binding^{100,99}. Considering that
 1086 $\Delta C_p^\circ = C_{p-complex}^\circ - (C_{p-BSA}^\circ + C_{p-ENRO}^\circ)$, a positive ΔC_p° indicates that the BSA-ENRO
 1087 complex has more ability to transfer heat energy to the potential forms than the free
 1088 BSA and ENRO molecules. This superior capability is due the new intermolecular
 1089 interactions formed when the complex is formed, that is, the interactions between BSA-
 1090 ENRO and complex-H₂O dominate the H₂O-H₂O interactions. The negative $T\Delta S^\circ$
 1091 values corroborates this positive ΔC_p° value, because they suggest that the system
 1092 entropy decreasing became from the formation of new intermolecular interactions
 1093 between BSA and ENRO. These new interactions increase the contributions of
 1094 potential energy for the total system energy.

1095 The value of ΔC_p° provides information not only about energy, but also on the
 1096 structural data and the reorganization of the solvent during complex formation¹⁰¹. Thus,
 1097 the ΔC_p° value is also related to the amount of hydrophobic surface area exposed. The
 1098 positive ΔC_p° value indicates the solvation of hydrophobic regions, i.e., after the
 1099 formation of the complex there was a greater exposure of the apolar
 1100 regions^{102,95,98,103,104}, caused by the protein conformational change induced by
 1101 interactions with ENRO.

1102 **4. Conclusions**

1103 ENRO showed to bind the BSA at physiological pH, the interaction being
1104 reduced with increasing temperature. Probes experiments revealed that ENRO binds
1105 preferentially to subdomain IIA (site I) of BSA, containing hydrophobic and positively
1106 charged regions. After the thermodynamic study it was found that the fluorescence
1107 quenching process was exothermic and that the complex formed is more stable than
1108 the free molecules. The formation of the BSA-ENRO complex was a process
1109 accompanied by the ECC phenomenon, where the enthalpy increase was
1110 compensated by the increase of the entropy. In addition, it was found that the new
1111 interactions that occur for complex formation (BSA-ENRO) increase the contributions of
1112 potential energy to the total energy of the system, that is, the complex formed (BSA-
1113 ENRO) had a greater capacity to transfer energy to the potential forms than the free
1114 molecules.

1115 This more detailed thermodynamic study, which reflects theoretical data on the
1116 interaction between BSA and ENRO, may be a useful guide in the use of BSA as
1117 carrier, providing some important data for the clinical study of the drug, with great
1118 significance in clinical medicine.

1119 **Acknowledgments**

1120 We are grateful to the Coordenação de Aperfeiçoamento de Pessoal de Nível
1121 Superior – Brasil (CAPES) – Finance Code 001, Conselho Nacional de
1122 Desenvolvimento Científico e Tecnológico and Fundação de Amparo à Pesquisa do
1123 Estado de Minas Gerais for the financial support.

1124 **5. References**

- 1125 (1) Farnaud, S.; Evans, R. W. Lactoferrin - A multifunctional protein with
1126 antimicrobial properties. *Mol. Immunol.* **2003**, *40* (7), 395–405.
- 1127 (2) Steijns, J. M.; van Hooijdonk, A. C. M. Occurrence, structure, biochemical
1128 properties and technological characteristics of lactoferrin. *Br. J. Nutr.* **2000**, *84*
1129 (S1).
- 1130 (3) Croguennec, T.; Li, N.; Phelebon, L.; Garnier-Lambrouin, F.; Gésan-Guiziou, G.
1131 Interaction between lactoferrin and casein micelles in skimmed milk. *Int. Dairy J.*

- 1132 **2012**, 27 (1–2), 34–39.
- 1133 (4) Darwish, S.; Mozaffari, S.; Parang, K.; Tiwari, R. Cyclic peptide conjugate of
1134 curcumin and doxorubicin as an anticancer agent. *Tetrahedron Lett.* **2017**, 58
1135 (49), 4617–4622.
- 1136 (5) Hussain, Z.; Thu, H. E.; Amjad, M. W.; Hussain, F.; Ahmed, T. A.; Khan, S.
1137 Exploring recent developments to improve antioxidant, anti-inflammatory and
1138 antimicrobial efficacy of curcumin: A review of new trends and future
1139 perspectives. *Mater. Sci. Eng. C* **2017**, 77, 1316–1326.
- 1140 (6) Ward, P. P.; Paz, E.; Conneely, O. M. Multifunctional roles of lactoferrin: A
1141 critical overview. *Cell. Mol. Life Sci.* **2005**, 62 (22), 2540–2548.
- 1142 (7) Sreedhara, A.; Flengsrud, R.; Langsrud, T.; Kaul, P.; Prakash, V.; Vegarud, G.
1143 E. Structural characteristic, pH and thermal stabilities of apo and holo forms of
1144 caprine and bovine lactoferrins. *BioMetals* **2010**, 23 (6), 1159–1170.
- 1145 (8) Ripolles, D.; Harouna, S.; Parrón, J. A.; Calvo, M.; Pérez, M. D.; Carramiñana, J.
1146 J.; Sánchez, L. Antibacterial activity of bovine milk lactoferrin and its
1147 hydrolysates prepared with pepsin, chymosin and microbial rennet against
1148 foodborne pathogen *Listeria monocytogenes*. *Int. Dairy J.* **2015**, 45, 15–22.
- 1149 (9) Iglesias-Figueroa, B. F.; Espinoza-Sánchez, E. A.; Siqueiros-Cendón, T. S.;
1150 Rascón-Cruz, Q. Lactoferrin as a nutraceutical protein from milk, an overview.
1151 *Int. Dairy J.* **2019**, 89, 37–41.
- 1152 (10) Bokkhim, H.; Bansal, N.; Grøndahl, L.; Bhandari, B. Interactions between
1153 different forms of bovine lactoferrin and sodium alginate affect the properties of
1154 their mixtures. *Food Hydrocoll.* **2015**, 48, 38–46.
- 1155 (11) Wakabayashi, H.; Yamauchi, K.; Takase, M. Lactoferrin research, technology
1156 and applications. *Int. Dairy J.* **2006**, 16 (11), 1241–1251.
- 1157 (12) TOMITA, M.; WAKABAYASHI, H.; SHIN, K.; YAMAUCHI, K.; YAESHIMA, T.;
1158 IWATSUKI, K. Twenty-five years of research on bovine lactoferrin applications.
1159 *Biochimie* **2009**, 91 (1), 52–57.
- 1160 (13) Yang, W.; Liu, F.; Xu, C.; Yuan, F.; Gao, Y. Molecular interaction between (-)-
1161 epigallocatechin-3-gallate and bovine lactoferrin using multi-spectroscopic
1162 method and isothermal titration calorimetry. *Food Res. Int.* **2014**, 64, 141–149.
- 1163 (14) Ferraro, V.; Madureira, A. R.; Sarmiento, B.; Gomes, A.; Pintado, M. E. Study of
1164 the interactions between rosmarinic acid and bovine milk whey protein α -
1165 Lactalbumin, β -Lactoglobulin and Lactoferrin. *Food Res. Int.* **2015**, 77, 450–459.
- 1166 (15) Jain, B. A spectroscopic study on stability of curcumin as a function of pH in
1167 silica nanoformulations, liposome and serum protein. *J. Mol. Struct.* **2017**, 1130,
1168 194–198.
- 1169 (16) Stankovic, I. Curcumin. *Joint FAO/WHO Expert Committee on Food Additives*.
1170 2004, pp 1–8.
- 1171 (17) Bharal, N.; Sahaya, K.; Jain, S.; Mediratta, P. K.; Sharma, K. K. Curcumin has
1172 anticonvulsant activity on increasing current electroshock seizures in mice.
1173 *Phyther. Res.* **2008**, 22 (12), 1660–1664.
- 1174 (18) Noratto, G. D.; Jutooru, I.; Safe, S.; Angel-Morales, G.; Mertens-Talcott, S. U.
1175 The drug resistance suppression induced by curcuminoids in colon cancer SW-
1176 480 cells is mediated by reactive oxygen species-induced disruption of the
1177 microRNA-27a-ZBTB10-Sp axis. *Mol. Nutr. Food Res.* **2013**, 57 (9), 1638–1648.
- 1178 (19) Ying, M.; Huang, F.; Ye, H.; Xu, H.; Shen, L.; Huan, T.; Huang, S.; Xie, J.; Tian,
1179 S.; Hu, Z.; et al. Study on interaction between curcumin and pepsin by
1180 spectroscopic and docking methods. *Int. J. Biol. Macromol.* **2015**, 79, 201–208.

- 1181 (20) Shin, G. H.; Li, J.; Cho, J. H.; Kim, J. T.; Park, H. J. Enhancement of Curcumin
1182 Solubility by Phase Change from Crystalline to Amorphous in Cur-TPGS
1183 Nanosuspension. *J. Food Sci.* **2016**, *81* (2), N494–N501.
- 1184 (21) Maiti, K.; Mukherjee, K.; Gantait, A.; Saha, B. P.; Mukherjee, P. K. Curcumin–
1185 phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic
1186 study in rats. *Int. J. Pharm.* **2007**, *330* (1–2), 155–163.
- 1187 (22) Wang, X.; Jiang, Y.; Wang, Y.-W.; Huang, M.-T.; Ho, C.-T.; Huang, Q.
1188 Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions.
1189 *Food Chem.* **2008**, *108* (2), 419–424.
- 1190 (23) Ge, Y.-S.; Jin, C.; Song, Z.; Zhang, J.-Q.; Jiang, F.-L.; Liu, Y. Multi-spectroscopic
1191 analysis and molecular modeling on the interaction of curcumin and its
1192 derivatives with human serum albumin: A comparative study. *Spectrochim. Acta*
1193 *Part A Mol. Biomol. Spectrosc.* **2014**, *124*, 265–276.
- 1194 (24) Mangolim, C. S.; Moriwaki, C.; Nogueira, A. C.; Sato, F.; Baesso, M. L.; Neto, A.
1195 M.; Matioli, G. Curcumin– β -cyclodextrin inclusion complex: Stability, solubility,
1196 characterisation by FT-IR, FT-Raman, X-ray diffraction and photoacoustic
1197 spectroscopy, and food application. *Food Chem.* **2014**, *153*, 361–370.
- 1198 (25) Esmaili, M.; Ghaffari, S. M.; Moosavi-Movahedi, Z.; Atri, M. S.; Sharifzadeh, A.;
1199 Farhadi, M.; Yousefi, R.; Chobert, J.-M.; Haertlé, T.; Moosavi-Movahedi, A. A.
1200 Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin;
1201 food industry application. *LWT - Food Sci. Technol.* **2011**, *44* (10), 2166–2172.
- 1202 (26) Hudson, E. A.; de Paula, H. M. C.; Ferreira, G. M. D.; Ferreira, G. M. D.;
1203 Hespanhol, M. do C.; da Silva, L. H. M.; Pires, A. C. dos S. Thermodynamic and
1204 kinetic analyses of curcumin and bovine serum albumin binding. *Food Chem.*
1205 **2018**, *242*, 505–512.
- 1206 (27) García-Montoya, I. A.; Cendón, T. S.; Arévalo-Gallegos, S.; Rascón-Cruz, Q.
1207 Lactoferrin a multiple bioactive protein: An overview. *Biochim. Biophys. Acta -*
1208 *Gen. Subj.* **2012**, *1820* (3), 226–236.
- 1209 (28) Sharma, S.; Sinha, M.; Kaushik, S.; Kaur, P.; Singh, T. P. C-lobe of lactoferrin:
1210 The whole story of the half-molecule. *Biochem. Res. Int.* **2013**, No. May.
- 1211 (29) Bollimpelli, V. S.; Kumar, P.; Kumari, S.; Kondapi, A. K. Neuroprotective effect of
1212 curcumin-loaded lactoferrin nano particles against rotenone induced
1213 neurotoxicity. *Neurochem. Int.* **2016**, *95*, 37–45.
- 1214 (30) Atrahimovich, D.; Vaya, J.; Tavori, H.; Khatib, S. Glabridin Protects Paraoxonase
1215 1 from Linoleic Acid Hydroperoxide Inhibition via Specific Interaction: A
1216 Fluorescence-Quenching Study. *J. Agric. Food Chem.* **2012**, *60* (14), 3679–
1217 3685.
- 1218 (31) Schasfoort, R. B. M.; Tudos, A. J. *Handbook of Surface Plasmon Resonance*;
1219 2013; Vol. 53.
- 1220 (32) Atale, S. S.; Dyawanapelly, S.; Jagtap, D. D.; Jain, R.; Dandekar, P.
1221 Understanding the nano-bio interactions using real-time surface plasmon
1222 resonance tool. *Int. J. Biol. Macromol.* **2019**, *123*, 97–107.
- 1223 (33) Gombau, J.; Nadal, P.; Canela, N.; Gómez-Alonso, S.; García-Romero, E.;
1224 Smith, P.; Hermosín-Gutiérrez, I.; Canals, J. M.; Zamora, F. Measurement of the
1225 interaction between mucin and oenological tannins by Surface Plasmon
1226 Resonance (SPR); relationship with astringency. *Food Chem.* **2019**, *275*, 397–
1227 406.
- 1228 (34) de Paula, H. M. C.; Coelho, Y. L.; Agudelo, A. J. P.; Rezende, J. de P.; Ferreira,
1229 G. M. D.; Ferreira, G. M. D.; Pires, A. C. dos S.; da Silva, L. H. M. Kinetics and
1230 thermodynamics of bovine serum albumin interactions with Congo red dye.

- 1231 *Colloids Surfaces B Biointerfaces* **2017**, *159*, 737–742.
- 1232 (35) Bi, H.; Tang, L.; Gao, X.; Jia, J.; Lv, H. Spectroscopic analysis on the binding
1233 interaction between tetracycline hydrochloride and bovine proteins β -casein, α -
1234 lactalbumin. *J. Lumin.* **2016**, *178*, 72–83.
- 1235 (36) Lakowicz, J. R. *Principles of fluorescence spectroscopy*; 2006.
- 1236 (37) Silva, M. S.; García-Estévez, I.; Brandão, E.; Mateus, N.; de Freitas, V.; Soares,
1237 S. Molecular Interaction Between Salivary Proteins and Food Tannins. *J. Agric. Food Chem.* **2017**, *65* (31), 6415–6424.
1238
- 1239 (38) Lelis, C. A.; Hudson, E. A.; Ferreira, G. M. D.; Ferreira, G. M. D.; da Silva, L. H.
1240 M.; da Silva, M. do C. H.; Pinto, M. S.; Pires, A. C. dos S. Binding
1241 thermodynamics of synthetic dye Allura Red with bovine serum albumin. *Food Chem.* **2017**, *217*, 52–58.
1242
- 1243 (39) Nunes, N. M.; Pacheco, A. F. C.; Agudelo, Á. J. P.; da Silva, L. H. M.; Pinto, M.
1244 S.; Hespanhol, M. do C.; Pires, A. C. dos S. Interaction of cinnamic acid and
1245 methyl cinnamate with bovine serum albumin: A thermodynamic approach. *Food Chem.* **2017**, *237*, 525–531.
1246
- 1247 (40) Mohammadi, F.; Moeeni, M. Study on the interactions of trans-resveratrol and
1248 curcumin with bovine α -lactalbumin by spectroscopic analysis and molecular
1249 docking. *Mater. Sci. Eng. C* **2015**, *50*, 358–366.
- 1250 (41) Mohammadi, F.; Bordbar, A.-K.; Divsalar, A.; Mohammadi, K.; Saboury, A. A.
1251 Interaction of Curcumin and Diacetylcurcumin with the Lipocalin Member β -
1252 Lactoglobulin. *Protein J.* **2009**, *28* (3–4), 117–123.
- 1253 (42) Bolel, P.; Mahapatra, N.; Halder, M. Optical Spectroscopic Exploration of Binding
1254 of Cochineal Red A with Two Homologous Serum Albumins. *J. Agric. Food Chem.* **2012**, *60*, 3727–3734.
1255
- 1256 (43) Patching, S. G. Surface plasmon resonance spectroscopy for characterisation of
1257 membrane protein–ligand interactions and its potential for drug discovery.
1258 *Biochim. Biophys. Acta - Biomembr.* **2014**, *1838* (1), 43–55.
- 1259 (44) Ferrante, A.; Gorski, J. Enthalpy-entropy compensation and cooperativity as
1260 thermodynamic epiphenomena of structural flexibility in ligand-receptor
1261 interactions. *J. Mol. Biol.* **2012**, *417* (5), 454–467.
- 1262 (45) Bou-Abdallah, F.; Sprague, S. E.; Smith, B. M.; Giffune, T. R. Binding
1263 thermodynamics of Diclofenac and Naproxen with human and bovine serum
1264 albumins: A calorimetric and spectroscopic study. *J. Chem. Thermodyn.* **2016**,
1265 *103*, 299–309.
- 1266 (46) Niedzwiecka, A.; Stepinski, J.; Darzynkiewicz, E.; Sonenberg, N.; Stolarski, R.
1267 Positive Heat Capacity Change upon Specific Binding of Translation Initiation
1268 Factor eIF4E to mRNA 5' Cap Positive Heat Capacity Change upon Specific
1269 Binding of Translation Initiation Factor eIF4E to mRNA 5' Cap †. *Biochemistry*
1270 **2002**, 12140–12148.
- 1271 (47) Perozzo, R.; Folkers, G.; Scapozza, L. Thermodynamics of protein-ligand
1272 interactions: History, presence, and future aspects. *J. Recept. Signal Transduct.*
1273 **2004**, *24* (1–2), 1–52.
- 1274 (48) Smith, I. W. M. The temperature-dependence of elementary reaction rates:
1275 beyond Arrhenius. *Chem. Soc. Rev.* **2008**, *37* (4), 812–826.
- 1276 (49) Pan, A.; Biswas, T.; Rakshit, A. K.; Moulik, S. P. Enthalpy–Entropy
1277 Compensation (EEC) Effect: A Revisit. *J. Phys. Chem. B* **2015**, *119* (52), 15876–
1278 15884.
- 1279 (50) Cheng, L.-Y.; Xia, W.; Zhang, X.; Bai, A.-M.; Ouyang, Y.; Hu, Y.-J. In vitro
1280 binding comparison of cephalosporins to human serum albumin by spectroscopy

- 1281 and molecular docking approaches: A novel structural pursuing. *J. Mol. Liq.*
1282 **2017**, *248*, 168–176.
- 1283 (51) KuKanich, B.; Gehring, R.; Webb, A. I.; Craigmill, A. L.; Riviere, J. E. Effect of
1284 formulation and route of administration on tissue residues and withdrawal times.
1285 *J. Am. Vet. Med. Assoc.* **2005**, *227* (10), 1574–1577.
- 1286 (52) Martins, M. T.; Barreto, F.; Hoff, R. B.; Jank, L.; Arsand, J. B.; Motta, T. M. C.;
1287 Schapoval, E. E. S. Multiclass and multi-residue determination of antibiotics in
1288 bovine milk by liquid chromatography–tandem mass spectrometry: Combining
1289 efficiency of milk control and simplicity of routine analysis. *Int. Dairy J.* **2016**, *59*,
1290 44–51.
- 1291 (53) BROWN, S. A. Fluoroquinolones in animal health. *J. Vet. Pharmacol. Ther.*
1292 **1996**, *19* (1), 1–14.
- 1293 (54) Attili, A. R.; Prezioso, S.; Ngu Ngwa, V.; Cantalamessa, A.; Moriconi, M.; Cuteri,
1294 V. Clinical evaluation of the use of enrofloxacin against *Staphylococcus aureus*
1295 clinical mastitis in sheep. *Small Rumin. Res.* **2016**, *136*, 72–77.
- 1296 (55) Giguère, S.; Dowling, P. M. Fluoroquinolones. In *Antimicrobial Therapy in*
1297 *Veterinary Medicine*; John Wiley & Sons, Inc: Hoboken, NJ, 2013; pp 295–314.
- 1298 (56) Idowu, O. R.; Peggins, J. O.; Cullison, R.; Bredow, J. von. Comparative
1299 pharmacokinetics of enrofloxacin and ciprofloxacin in lactating dairy cows and
1300 beef steers following intravenous administration of enrofloxacin. *Res. Vet. Sci.*
1301 **2010**, *89* (2), 230–235.
- 1302 (57) Liu, Z.; Chan, L.; Ye, X.; Bai, Y.; Chen, T. BSA-Based Cu₂Se Nanoparticles
1303 with Multistimuli-Responsive Drug Vehicles for Synergistic Chemo-Photothermal
1304 Therapy. *Colloids Surfaces B Biointerfaces* **2018**.
- 1305 (58) Salehiabar, M.; Nosrati, H.; Javani, E.; Aliakbarzadeh, F.; Kheiri Manjili, H.;
1306 Davaran, S.; Danafar, H. Production of biological nanoparticles from bovine
1307 serum albumin as controlled release carrier for curcumin delivery. *Int. J. Biol.*
1308 *Macromol.* **2018**, *115*, 83–89.
- 1309 (59) McCann, D.; Barrett, A.; Cooper, A.; Crumpler, D.; Dalen, L.; Grimshaw, K.;
1310 Kitchin, E.; Lok, K.; Porteous, L.; Prince, E.; et al. Food additives and
1311 hyperactive behaviour in 3-year-old and 8/9-year-old children in the community:
1312 a randomised, double-blinded, placebo-controlled trial. *Lancet* **2007**, *370* (9598),
1313 1560–1567.
- 1314 (60) Lin, Y.; Jiao, G.; Sun, G.; Zhang, L.; Wang, S.; Liu, H.; Li, Z. Binding of
1315 teicoplanin and vancomycin to bovine serum albumin in vitro: A
1316 multispectroscopic approach and molecular modeling. *Luminescence* **2014**, *29*
1317 (2), 109–117.
- 1318 (61) Jattinagoudar, L.; Meti, M.; Nandibewoor, S.; Chimatadar, S. Evaluation of the
1319 binding interaction between bovine serum albumin and dimethyl fumarate, an
1320 anti-inflammatory drug by multispectroscopic methods. *Spectrochim. Acta - Part*
1321 *A Mol. Biomol. Spectrosc.* **2016**, *156*, 164–171.
- 1322 (62) Guo, M.; Lu, W.-J.; Yi, P.-G.; Yu, Q.-S. Study on the thermodynamic
1323 characteristics between fluoroquinolone and bovine serum albumin. *J. Chem.*
1324 *Thermodyn.* **2007**, *39* (3), 337–343.
- 1325 (63) Seedher, N.; Agarwal, P. Complexation of fluoroquinolone antibiotics with human
1326 serum albumin: A fluorescence quenching study. *J. Lumin.* **2010**, *130* (10),
1327 1841–1848.
- 1328 (64) Liu, B.; Xue, C.; Wang, J.; Yang, C.; Lv, Y. Study of the quenching mechanism
1329 of bovine serum albumin with presence of chloramphenicol and enrofloxacin.
1330 *Phys. Chem.* **2011**, *6* (2).

- 1331 (65) Ni, Y.; Su, S.; Kokot, S. Spectrometric studies on the interaction of
1332 fluoroquinolones and bovine serum albumin. *Spectrochim. Acta - Part A Mol.*
1333 *Biomol. Spectrosc.* **2010**, *75* (2), 547–552.
- 1334 (66) Reddy, T. K.; Srikanth, G.; Mallikarjun, V.; Nivethithai, P. MECHANISM OF
1335 INTERACTION OF SOME ANTIMICROBIAL AGENTS WITH BOVINE SERUM
1336 ALBUMIN. *J. Glob. Pharma Technol.* **2009**, *2* (March 2010), 47–55.
- 1337 (67) Qin, P.; Pan, X.; Liu, R.; Hu, C.; Dong, Y. Toxic interaction mechanism of two
1338 fluoroquinolones with serum albumin by spectroscopic and computational
1339 methods. *J. Environ. Sci. Heal. - Part B Pestic. Food Contam. Agric. Wastes*
1340 **2017**, *52* (11), 833–841.
- 1341 (68) Wang, L.; Zhang, G.; Wang, Y. Binding properties of food colorant allura red with
1342 human serum albumin in vitro. *Mol. Biol. Rep.* **2014**, *41* (5), 3381–3391.
- 1343 (69) Ma, L.; Liu, B.; Wang, C.; Zhang, H.; Cheng, X. The Investigation of
1344 Fluorescence Spectra and Fluorescence Quantum Yield of Enrofloxacin. **2018**, *2*
1345 (1), 11–16.
- 1346 (70) Lizondo, M.; Pons, M.; Gallardo, M.; Estelrich, J. Physicochemical properties of
1347 enrofloxacin. *J. Pharm. Biomed. Anal.* **1997**, *15* (12), 1845–1849.
- 1348 (71) Bi, S.; Song, D.; Tian, Y.; Zhou, X.; Liu, Z.; Zhang, H. Molecular spectroscopic
1349 study on the interaction of tetracyclines with serum albumins. *Spectrochim. Acta*
1350 *- Part A Mol. Biomol. Spectrosc.* **2005**, *61* (4), 629–636.
- 1351 (72) Schneider, M. J. Rapid Fluorescence Screening Assay for Enrofloxacin and
1352 Tetracyclines in Chicken Muscle. *J. Agric. Food Chem.* **2004**, *52* (26), 7809–
1353 7813.
- 1354 (73) Yazdi, S. R.; Corredig, M. Heating of milk alters the binding of curcumin to
1355 casein micelles . A fluorescence spectroscopy study. *Food Chem.* **2012**, *132* (3),
1356 1143–1149.
- 1357 (74) Benesi, H. A.; Hildebrand, J. H. a Spectrophotometric Investigation of the
1358 Interaction of Iodine With Aromatic Hydrocarbons. *J. Am. Chem. Soc.* **1949**, *71*
1359 (8), 2703–2707.
- 1360 (75) Bensouilah, N.; Abdaoui, M. Inclusion complex of N-nitroso, N-(2-chloroethyl),
1361 N', N'-dibenzylsulfamid with β -Cyclodextrin: Fluorescence and molecular
1362 modeling. *Comptes Rendus Chim.* **2012**, *15* (11–12), 1022–1036.
- 1363 (76) Otagiri, M. A Molecular Functional Study on the Interactions of Drugs with
1364 Plasma Proteins. *Drug Metab. Pharmacokinet.* **2005**, *20* (5), 309–323.
- 1365 (77) Roy, S. Review on Interaction of Serum Albumin with Drug Molecules. *Res. Rev.*
1366 *J. Pharmacol. Toxicol. Stud.* **2016**, *4* (2), 1–10.
- 1367 (78) Ming Guo, Wei-Jun Lu, Ping-Gui Yi, Q.-S. Y. Study on the thermodynamic
1368 characteristics between fluoroquinolone and bovine serum albumin. *J. Chem.*
1369 *Thermodyn.* **2007**, *39*, 337–343.
- 1370 (79) Sinisi, V.; Forzato, C.; Cefarin, N.; Navarini, L.; Berti, F. Interaction of
1371 chlorogenic acids and quinides from coffee with human serum albumin. *FOOD*
1372 *Chem.* **2015**, *168*, 332–340.
- 1373 (80) Bourassa, P.; Kanakis, C. D.; Tarantilis, P.; Pollissiou, M. G.; Tajmir-Riahi, H. a.
1374 Resveratrol, genistein, and curcumin bind bovine serum albumin. *J. Phys.*
1375 *Chem. B* **2010**, *114* (9), 3348–3354.
- 1376 (81) Pal, U.; Pramanik, S. K.; Bhattacharya, B.; Banerji, B.; Maiti, N. C. Binding
1377 interaction of a novel fluorophore with serum albumins: steady state
1378 fluorescence perturbation and molecular modeling analysis. *Springerplus* **2015**,
1379 *4* (1).

- 1380 (82) Li, M.; Hagerman, A. E. Role of the Flavan-3-ol and Galloyl Moieties in the
1381 Interaction of (-)-Epigallocatechin Gallate with Serum Albumin. *J. Agric. Food*
1382 *Chem.* **2014**, *62* (17), 3768–3775.
- 1383 (83) Datta, S.; Mahapatra, N.; Halder, M. pH-insensitive electrostatic interaction of
1384 carmoisine with two serum proteins: A possible caution on its uses in food and
1385 pharmaceutical industry. *J. Photochem. Photobiol. B Biol.* **2013**, *124*, 50–62.
- 1386 (84) Majorek, K. A.; Porebski, P. J.; Dayal, A.; Zimmerman, M. D.; Jablonska, K.;
1387 Stewart, A. J.; Chruszcz, M.; Minor, W. Structural and immunologic
1388 characterization of bovine, horse, and rabbit serum albumins. *Mol. Immunol.*
1389 **2012**, *52* (3–4), 174–182.
- 1390 (85) Khatun, S.; Riyazuddeen; Yasmeen, S.; Kumar, A.; Subbarao, N. Calorimetric,
1391 spectroscopic and molecular modelling insight into the interaction of gallic acid
1392 with bovine serum albumin. *J. Chem. Thermodyn.* **2018**, *122*, 85–94.
- 1393 (86) Kaur, A.; Khan, I. A.; Banipal, P. K.; Banipal, T. S. Deciphering the complexation
1394 process of a fluoroquinolone antibiotic, levofloxacin, with bovine serum albumin
1395 in the presence of additives. *Spectrochim. Acta - Part A Mol. Biomol. Spectrosc.*
1396 **2018**, *191*, 259–270.
- 1397 (87) Yuan, J.-L.; Iv, Z.; Liu, Z.-G.; Hu, Z.; Zou, G.-L. Study on interaction between
1398 apigenin and human serum albumin by spectroscopy and molecular modeling. *J.*
1399 *Photochem. Photobiol. A Chem.* **2007**, *191* (2–3), 104–113.
- 1400 (88) Ross, P. D.; Subramanian, S. Thermodynamics of protein association reactions:
1401 forces contributing to stability. *Biochemistry* **1981**, *20* (11), 3096–3102.
- 1402 (89) Cui, F.-L.; Wang, J.-L.; Cui, Y.-R.; Li, J.-P. Fluorescent investigation of the
1403 interactions between N-(p-chlorophenyl)-N'-(1-naphthyl) thiourea and serum
1404 albumin: Synchronous fluorescence determination of serum albumin. *Anal.*
1405 *Chim. Acta* **2006**, *571* (2), 175–183.
- 1406 (90) Basu, A.; Kumar, G. S. Thermodynamics of the interaction of the food additive
1407 tartrazine with serum albumins: a microcalorimetric investigation. *Food Chem.*
1408 **2015**, *175*, 137–142.
- 1409 (91) Bou-Abdallah, F.; Sprague, S. E.; Smith, B. M.; Giffune, T. R. Binding
1410 thermodynamics of Diclofenac and Naproxen with human and bovine serum
1411 albumins: A calorimetric and spectroscopic study. *J. Chem. Thermodyn.* **2016**,
1412 *103*, 299–309.
- 1413 (92) Chaires, J. B. Calorimetry and Thermodynamics in Drug Design. *Annu. Rev.*
1414 *Biophys.* **2008**, *37* (1), 135–151.
- 1415 (93) Chodera, J. D.; Mobley, D. L. Entropy-enthalpy compensation: Role and
1416 ramifications in biomolecular ligand recognition and design. *Annu Rev Biophys*
1417 **2014**, *42*, 121–142.
- 1418 (94) Sturtevant, J. M. Heat capacity and entropy changes in processes involving
1419 proteins. *Proc. Natl. Acad. Sci.* **1977**, *74* (6), 2236–2240.
- 1420 (95) Perozzo, R.; Folkers, G.; Scapozza, L. Thermodynamics of protein-ligand
1421 interactions: history, presence, and future aspects. *J. Recept. Signal Transduct.*
1422 *Res.* **2004**, *24* (1–2), 1–52.
- 1423 (96) Saini, R. D. Thermodynamics of protein-ligand interactions and their analysis. *J.*
1424 *Proteins Proteomics* **2017**, *8* (4), 205–217.
- 1425 (97) Ford, D. M. Enthalpy–Entropy Compensation is Not a General Feature of Weak
1426 Association. *J. Am. Chem. Soc.* **2005**, *127* (46), 16167–16170.
- 1427 (98) Ball, V.; Maechling, C. Isothermal microcalorimetry to investigate non specific
1428 interactions in biophysical chemistry. *Int. J. Mol. Sci.* **2009**, *10* (8), 3283–3315.

- 1429 (99) Molina-Bolívar, J. A.; Ruiz, C. C.; Galisteo-González, F.; O'Donnell, M. M.;
1430 Parra, A. Energetics of albumin-disuccinylmaslinic acid binding determined by
1431 fluorescence spectroscopy. *Fluid Phase Equilib.* **2015**, *400*, 43–52.
- 1432 (100) Banerjee, T.; Singh, S. K.; Kishore, N. Binding of Naproxen and Amitriptyline to
1433 Bovine Serum Albumin: Biophysical Aspects. *J. Phys. Chem. B* **2006**, *110* (47),
1434 24147–24156.
- 1435 (101) Xu, Y.; Oruganti, S. V.; Gopalan, V.; Foster, M. P. Thermodynamics of coupled
1436 folding in the interaction of archaeal RNase P proteins RPP21 and RPP29.
1437 *Biochemistry* **2012**, *51* (4), 926–935.
- 1438 (102) Spolar, R.; Record, M. Coupling of local folding to site-specific binding of
1439 proteins to DNA. *Science* (80-.). **1994**, *263* (5148), 777–784.
- 1440 (103) Banipal, T. S.; Kaur, N.; Banipal, P. K. Binding studies of caffeine and
1441 theophylline to bovine serum albumin: Calorimetric and spectroscopic approach.
1442 *J. Mol. Liq.* **2016**, *223*, 1048–1055.
- 1443 (104) Vega, S.; Abian, O.; Velazquez-Campoy, A. On the link between conformational
1444 changes, ligand binding and heat capacity. *Biochim. Biophys. Acta - Gen. Subj.*
1445 **2016**, *1860* (5), 868–878.
- 1446

CONCLUSÃO GERAL

Proteínas do leite como BSA e lactoferrina demonstraram interagir com compostos de interesse na área de alimentos. Por espectroscopia de fluorescência foi possível verificar que lactoferrina interage com curcumina por meio de interações hidrofóbicas apresentando potencial para veicular um número significativo de curcumina. A determinação da constante de interação obtidas por espectroscopia de fluorescência e por ressonância plasmônica de superfície sugeriu que as interações que ocorrem nos sítios distantes dos resíduos de triptofano são mais fracas e acompanhadas de mudanças conformacionais nos sítios. Os parâmetros termodinâmicos e cinéticos determinados nesse estudo foram influenciados pela temperatura, sendo verificada a ocorrência do fenômeno de compensação entálpica-entropia. Através do estudo cinético também foi possível sugerir que nas baixas temperaturas estudadas a CUR interage na superfície na proteína, já em temperaturas mais elevadas o composto bioativo interage preferencialmente no interior da proteína.

No estudo de interação entre BSA e ENRO foi utilizada a capacidade da enrofloxacinolona de emitir fluorescência, sendo portanto um estudo baseado em uma propriedade do ligante. Por espectroscopia de fluorescência a ENRO demonstrou se ligar preferencialmente ao sítio I da BSA, em pH fisiológico. O processo de interação foi influenciado pela variação de temperatura, sendo também verificada a ocorrência do fenômeno de compensação entálpica-entropia, onde a diminuição da entalpia com o aumento da temperatura foi compensado pelo aumento da entropia.

Assim, o estudo realizado pode ser útil, em futuras aplicações das proteínas do leite como estruturas de transporte para diversas moléculas.